

CITATION REPORT

List of articles citing

Prasugrel versus clopidogrel in patients with acute coronary syndromes

DOI: 10.1056/nejmoa0706482

New England Journal of Medicine, 2007, 357, 2001-15.

Source: <https://exaly.com/paper-pdf/42431152/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2226	.		
2225	HERBERT DINGLE [1972]: Science at the Crossroads. London: Martin Brian and O'Keeffe. Pp. 256. £3.00. 1975 , 26, 358-362		2
2224	Human U1 small nuclear RNA pseudogenes do not map to the site of the U1 genes in 1p36 but are clustered in 1q12-q22. 1985 , 5, 2172-80		41
2223	Sequential proteome alterations during genesis and progression of colon cancer. 2004 , 61, 1246-55		65
2222	Proteins interacting with the 26S proteasome. 2004 , 61, 1589-95		32
2221	Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. 2004 , 61, 1975-84		46
2220	Emerging roles of thioredoxin cycle enzymes in the central nervous system. 2005 , 62, 1063-80		84
2219	Intensifying platelet inhibition--navigating between Scylla and Charybdis. <i>New England Journal of Medicine</i> , 2007 , 357, 2078-81	59.2	136
2218	Issue Highlights. 2007 , 116, 2893-2893		
2217	Bleeding is bad.... isn't it?. 2007 , 116, 2776-8		9
2216	Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. 2007 , 116, 2923-32		718
2215	Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. 2008 , 29, 21-30		356
2214	ADP receptor antagonism: what's in the pipeline?. 2007 , 7, 423-32		43
2213	Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. 2007 , 25, 357-74		204
2212	Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. 2008 , 1, 62-4		4
2211	Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 2008 , 1, 111-21		40
2210	Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. 2008 , 1, 649-53		120

2209	The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. 2008 , 1, 612-9	43
2208	High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment. 2008 , 22, 407-18	5
2207	Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. 2008 , 35, 593-618	44
2206	Drug-eluting coronary stent very late thrombosis revisited. 2008 , 33, 334-42	22
2205	[Resistance to antiplatelet substances--a real clinical problem]. 2008 , 33, 260-8	3
2204	[Clopidogrel--clinical use and potential therapeutic problems]. 2008 , 33, 280-6	2
2203	[Optimal platelet inhibition after coronary stent implantation. Current status]. 2008 , 33, 244-53	4
2202	Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. 2008 , 64, 227-32	1
2201	[Antithrombotic therapy of acute myocardial infarction]. 2008 , 49, 1031-7	
2200	Thrombozytenfunktion bei Diabetes mellitus. 2008 , 4, 429-434	
2199	Clopidogrel and coronary stents: risks and benefits. 2008 , 10, 303-8	
2198	Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. 2008 , 10, 367-8	
2197	Optimal treatment of the diabetic patient with multivessel disease. 2008 , 10, 272-84	1
2196	New data on early management of patients with ST-elevation myocardial infarction. 2008 , 10, 291-8	
2195	Antiplatelet therapy in acute coronary syndromes. 2008 , 10, 327-33	5
2194	Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association. 2008 , 97, 1-11	10
2193	[Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK]. 2008 , 97, 548-63	26
2192	Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. 2008 , 6, 1	20

2191	The feasibility and safety of routine thrombus aspiration in patients with non-ST-elevation myocardial infarction. 2008 , 72, 937-42	25
2190	Clopidogrel under scrutiny. 2008 , 72, 925-6	
2189	Progress in secondary stroke prevention. 2008 , 63, 418-27	19
2188	Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. 2008 , 1, 369-78	42
2187	Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. 2008 , 1, 631-8	102
2186	Resisting the temptation to oversimplify antiplatelet resistance. 2008 , 1, 660-2	5
2185	Reperfusion strategies in ST-elevation myocardial infarction--current status and perspectives for early and pre-hospital treatment. 2008 , 77, 296-305	6
2184	Antiplatelet therapy and platelet function testing. 2008 , 31, 136	5
2183	Muddy waters: more stormy SEAS for ezetimibe. 2008 , 62, 1470-3	11
2182	Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 2008 , 21, 283-99	2
2181	The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. 2008 , 21 Suppl 1, S10-7	8
2180	Advances in antiplatelet therapy for ACS and PCI. 2008 , 21 Suppl 1, S18-24	5
2179	Triggers, targets and treatments for thrombosis. 2008 , 451, 914-8	736
2178	Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. 2008 , 6, 837-45	9
2177	The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. 2008 , 6, 1153-9	84
2176	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. 2008 , 6, 1824-6	15
2175	The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. 2008 , 6, 2210-3	11
2174	Dipyridamole, cerebrovascular disease, and the vasculature. 2008 , 48, 143-9	49

2173	Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). 2008 , 101, 1364-6	12
2172	Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. 2008 , 101, 1700-3	59
2171	A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. 2008 , 101, 1367-70	9
2170	Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). 2008 , 102, 1017-22	15
2169	Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). 2008 , 102, 1335-40	7
2168	Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention. 2008 , 102, 1318-22	16
2167	Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. 2008 , 102, 1614-7	105
2166	Drug-eluting stents and antiplatelet resistance. 2008 , 102, 29J-37J	5
2165	Platelet activation, and antiplatelet targets and agents: current and novel strategies. 2008 , 68, 1647-64	11
2164	Antithrombotic therapies in primary angioplasty: rationale, results and future directions. 2008 , 68, 2325-44	6
2163	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association 2007 (Orlando, EE.UU., 4-7 de noviembre de 2007). 2008 , 61, 185-193	11
2162	Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. 2008 , 61, 501-513	35
2161	Major bleeding: management and risk reduction in acute coronary syndromes. 2008 , 9, 1869-83	8
2160	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Orlando, USA, November 4-7, 2007). 2008 , 61, 185-193	
2159	Coronary Atherothrombotic Disease: Progress in Antiplatelet Therapy. 2008 , 61, 501-513	
2158	The year in atherothrombosis. 2008 , 51, 944-55	11
2157	Clopidogrel resistance: more grist for the mill. 2008 , 51, 1935-7	12
2156	Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?. 2008 , 51, 1412-4	10

2155	The year in interventional cardiology. 2008 , 51, 2355-69	1
2154	Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. 2008 , 51, 2028-33	269
2153	Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late?. 2008 , 52, 790-1; author reply 791-2	2
2152	Reply. 2008 , 52, 791-792	1
2151	What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?. 2008 , 52, 1060-1	37
2150	The year in non-ST-segment elevation acute coronary syndrome. 2008 , 52, 1095-103	7
2149	Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. 2008 , 52, 1968-77	164
2148	Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 2008 , 52, 1693-701	160
2147	Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?. 2008 , 26, 629-37	5
2146	[New antiplatelet drugs]. 2008 , 37, 1055-68	
2145	Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. 2008 , 155, 648-53	26
2144	Antiplatelet drug nonresponsiveness. 2008 , 155, 591-9	40
2143	Clinical profile of prasugrel, a novel thienopyridine. 2008 , 156, S16-22	37
2142	Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. 2008 , 122, 523-32	24
2141	Conducting clinical trials: even more challenges. 2008 , 6, 99-100	3
2140	Monitoring oral antiplatelet therapy: is it justified?. 2008 , 2, 485-96	13
2139	Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. 2008 , 371, 1353-63	366
2138	Approaching an age of reason with antiplatelet therapy. 2008 , 371, 1315-6	7

2137	Intensive antiplatelet therapy for reduction of ischaemic events. 2008 , 372, 531; author reply 532	1
2136	Acute myocardial infarction. 2008 , 372, 570-84	466
2135	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. 2008 , 372, 1163-73	531
2134	Optimisation de la prise en charge des patients avec un infarctus aigu du myocarde avec l'vation du segment ST: stratgies clS aux urgences et en prhospitalier. 2008 , 21, 138-146	0
2133	Antiplatelet agents and arterial thrombosis. 2008 , 26, 189-201, vi	8
2132	A paradigm shift in anti-platelet therapy?. 2008 , 19, 562-4	
2131	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. 2008 , 19, 595-604	89
2130	Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. 2008 , 8, 91-112	15
2129	Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes. 2008 , 8, 283-95	2
2128	Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. 2008 , 118, 1626-36	586
2127	Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. 2008 , 9, 377-86	5
2126	Current concepts about inhibition of platelet aggregation. 2008 , 19, 565-70	10
2125	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. 2008 , 29, 2202-11	161
2124	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. 2008 , 36, 421-35	153
2123	Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. 2008 , 29, 1389-94	106
2122	Rsistance aux antiagrants plaquettaires: expfience du SCA. 2008 , 33, S61-S62	
2121	Use of antiplatelet agents for prevention of ischemic stroke. 2008 , 26, 1047-77, ix	1
2120	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. 2008 , 5, 766-80	72

2119	Interaction between statins and clopidogrel: is there anything clinically relevant?. 2008 , 101, 915-25	35
2118	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. 2009 , 30, 900-7	102
2117	Safety of drug-eluting stents. 2008 , 5, 316-28	17
2116	Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. 2008 , 26, 93-4	12
2115	Translational therapeutics at the platelet vascular interface. Summary. 2008 , 28, s51-2	1
2114	Catheter-based treatment of coronary artery disease: past, present, and future. 2008 , 1, 60-73	17
2113	Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. 2008 , 118, 538-51	37
2112	Prasugrel: a novel antiplatelet agent. 2008 , 65, 1019-28	18
2111	How to react to high platelet reactivity?: reply. 2008 , 29, 1471-1472	
2110	Mild renal dysfunction associated with incident coronary artery disease in young males (from MELANY Study Investigators): reply. 2008 , 29, 1472-1473	
2109	Optimizing platelet inhibition. 2008 , 10, D23-D29	12
2108	Antiplatelet therapy in acute coronary syndromes. 2008 , 10, A4-A12	2
2107	Adjunctive antithrombotic therapy during primary percutaneous coronary intervention. 2008 , 10, J2-J14	
2106	Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. 2008 , 29, 1699-700	3
2105	The challenge of monitoring platelet response after clopidogrel. 2008 , 29, 2833-4	3
2104	ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 2009 , 30, 152-61	25
2103	What to do with patients receiving long-term clopidogrel: reload or relax?. 2008 , 118, 1219-22	5
2102	Commentary. Prasugrel versus clopidogrel in patients with acute coronary symptoms. 2008 , 20, 223-4	6

2101	Commentary. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. 2008 , 20, 224-6		
2100	Thrombosis after stent implantation: how much of a problem is there?. 2008 , 4, 261-7		6
2099	Bleeding risks with prasugrel in the TRITON trial: good news ... bad news. 2008 , 111, 265-7		2
2098	New developments in antiplatelet therapy. 2008 , 10, D30-D37		6
2097	Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. 2008 , 5, 138-44		83
2096	P2Y12 antagonism: promises and challenges. 2008 , 28, s33-8		78
2095	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. 2008 , 5, 580-9		51
2094	New antiplatelet therapies in development. 2008 , 65, S11-5; quiz S16-8		1
2093	For better or for worse: the future of antiplatelet therapy. 2008 , 65, 1017		3
2092	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2218-30	59.2	1457
2091	Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. 2008 , 118, 1225-33		73
2090	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely. 2008 , 1, 217-25		13
2089	Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. 2009 , 30, 908-15		108
2088	Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?. 2008 , 11, 541-6		1
2087	Prasugrel versus clopidogrel. <i>New England Journal of Medicine</i> , 2008 , 358, 1298; author reply 1299-301	59.2	6
2086	Antithrombotic therapy to support primary PCI. <i>New England Journal of Medicine</i> , 2008 , 358, 2280-2	59.2	12
2085	More on subgroup analyses in clinical trials. <i>New England Journal of Medicine</i> , 2008 , 358, 2076; author reply 2076-7	59.2	23
2084	Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. 2008 , 9, 2893-900		31

- 2083 Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development. **2008**, 10, I33-I37 7
- 2082 Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. **2008**, 299, 1788-99 214
- 2081 Treatment of ST-elevation myocardial infarction. **2008**, 4, 391-7
- 2080 Body fat and cardiovascular risk: understanding the obesity paradox. **2009**, 30, 752-4 26
- 2079 Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. **2008**, 2008, 292-294
- 2078 Mild renal dysfunction associated with incident coronary artery disease in young males (from MELANY Study Investigators). **2008**, 29, 1472; author reply 1472-3
- 2077 Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. **2008**, 10, I25-I29 5
- 2076 Dual antiplatelet therapy in the drug-eluting stent era. **2008**, 10, D38-D44 2
- 2075 Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. **2008**, 10, I8-I13
- 2074 When and how to discontinue antiplatelet therapy. **2008**, 10, A35-A41 11
- 2073 Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. **2008**, 108, 433-8 46
- 2072 Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. **2008**, 72, 1165-9 75
- 2071 New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). **2008**, 133, 234S-256S 186
- 2070 Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation. 143-163
- 2069 Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases. 215-229
- 2068 Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits. 231-250
- 2067 Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. **2008**, 29, 2473-9 109
- 2066 Antiplatelet therapy in percutaneous coronary intervention. **2008**, 10, A13-A20 6

2065	Unmet needs in antiplatelet therapy. 2008 , 10, D3-D11	5
2064	Clinical implications of the results of recent atherothrombotic trials on patient management. 2008 , 10, I30-I32	
2063	Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. 2008 , 16, 250-9	5
2062	Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. 2008 , 23, 302-8	7
2061	Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. 2008 , 16, 314-8	15
2060	Bibliography. Current world literature. Diseases of the aorta, pulmonary, and peripheral vessels. 2008 , 23, 646-7	
2059	Antithrombotische und thrombolytische Therapie beim akuten Koronarsyndrom. 2008 , 28, 438-447	
2058	. 2008 ,	1
2057	The P2Y 13 Met-158-Thr polymorphism, which is in linkage disequilibrium with the P2Y 12 locus, is not associated with acute myocardial infarction. 2008 , 3, e1462	9
2056	Antiplatelet drugs in cardiological practice: established strategies and new developments. 2008 , 4, 637-45	24
2055	Will prasugrel supersede clopidogrel for acute coronary syndromes?. 2008 , 188, 381-2	5
2054	Antiplatelet Resistanceâ€”Does it Exist and how to Measure it?. 2009 , 3, CMC.S2159	2
2053	Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. 2009 , 5, 101-19	11
2052	Prasugrel for the treatment of patients with acute coronary syndrome. 2009 , 5, 321-4	1
2051	Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. 2009 , 5, 475-81	4
2050	Clinical News. 2009 , 70, 256-259	
2049	Antiplatelet agents in stroke prevention. 2009 , 29, 326-333	4
2048	Improving antiplatelet therapy for atherothrombotic disease. 2009 , 29, 349-355	8

2047	P2Y12 inhibitors. 2009 , 29, 339-348	6
2046	. 2009 ,	0
2045	Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation. 2009 , 39, 459-61	4
2044	Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. 2009 , 1, CMT.S1170	
2043	Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2009 , 5, 677-91	
2042	Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. 2009 , 5, 873-82	26
2041	Critical review of prasugrel for formulary decision makers. 2009 , 15, 335-43	8
2040	Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. 2009 , 1, CMT.S2208	
2039	Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel. 2009 , 15, 414-6	1
2038	Another view on prasugrel. 2009 , 101, 12-13	2
2037	Review of prasugrel for the secondary prevention of atherothrombosis. 2009 , 15, 383-95	16
2036	The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. 2009 , 102, 916-24	101
2035	Incredibly late thromboses in first generation drug eluting stents: a case series. 2009 , 2, 9303	1
2034	Platelet P2Y12 receptor inhibition by thienopyridines: status and future. 2009 , 18, 1317-32	16
2033	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. 2009 , 25, 2631-41	16
2032	Cangrelor: a novel P2Y12 receptor antagonist. 2009 , 18, 1219-30	15
2031	Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. 2009 , 49, 984-98	67
2030	Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences. 2009 , 20, 498-504	4

2029	Platelet function testing and implications for clinical practice. 2009 , 14, 157-69		37
2028	Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis. 2009 , 49, 973-83		1
2027	Stopping the hemorrhage: a new baseline bleeding score brings us a step closer for patients with non-ST-elevation myocardial infarction. 2009 , 119, 1846-9		8
2026	Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. 2009 , 32, 531-40		97
2025	Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. 2009 , 37, 589-93		47
2024	Cangrelor - a champion lost in translation?. <i>New England Journal of Medicine</i> , 2009 , 361, 2382-4	59.2	19
2023	Ticagrelor--is there need for a new player in the antiplatelet-therapy field?. <i>New England Journal of Medicine</i> , 2009 , 361, 1108-11	59.2	103
2022	Intravenous platelet blockade with cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2330-41	59.2	480
2021	Antiplatelet agents. 2009 , 267-72		22
2020	A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. 2009 , 20, 302-15		2
2019	Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. 2009 , 7, 17-23		4
2018	Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. 2009 , 119, 2553-60		510
2017	Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. 2009 , 20, 531-8		12
2016	Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2318-29	59.2	454
2015	Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. 2009 , 5, 237-46		1
2014	Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. 2009 , CD001246		36
2013	Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. 2009 , 2, 222-9		242
2012	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. 2009 , 119, 2758-64		137

2011	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. 2009 , 7, 1525-32	1
2010	Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes. 2009 , 6, 619-20	1
2009	Bedside evaluation of thienopyridine antiplatelet therapy. 2009 , 119, 2625-32	111
2008	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 2009 , 119, 2877-85	371
2007	Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. 2009 , 120, 2586-96	139
2006	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 , 120, 2271-306	820
2005	Left Main Coronary Artery Disease. 2009 ,	
2004	Weighing benefits and risks--the FDA's review of prasugrel. <i>New England Journal of Medicine</i> , 2009 , 361, 942-5	59.2 86
2003	Letter by Rosenstein and Parra regarding article, "Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel: Thrombolysis in Myocardial Infarction 38". 2009 , 119, e601; author reply e602-3	
2002	Update on dual antiplatelet therapy for percutaneous coronary intervention. 2009 , 95, 861-5	2
2001	SCH 530348: a novel oral thrombin receptor antagonist. 2009 , 5, 435-42	13
2000	The FDA prasugrel review: adjudication of myocardial infarction controversy. 2009 , 114, 126-9	7
1999	New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. 2009 , 30, 1695-702	13
1998	Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. 2009 , 30, 2556-7	
1997	Platelet interactions as therapeutic targets for prevention of atherothrombosis. 2009 , 5, 285-96	2
1996	Balancing efficacy and safety in the TRITON-TIMI 38 trial. 2009 , 11, G14-G17	4
1995	Fast, potent, and reliable inhibition of platelet aggregation. 2009 , 11, G9-G13	1
1994	Conclusions. 2009 , 11, G25-G26	

1993	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. 2009 , 30, 2714-21		199
1992	The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. 2009 , 121, 59-72		4
1991	Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies. 2009 , 5, 385-402		10
1990	Cangrelor in percutaneous coronary intervention. 2009 , 2, 137-45		3
1989	The P2Y12 receptor: no active metabolite, no party. 2009 , 6, 271-2		15
1988	Ticagrelor versus clopidogrel in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 2385; author reply 2387-8	59.2	9
1987	Prasugrel in clinical practice. <i>New England Journal of Medicine</i> , 2009 , 361, 940-2	59.2	70
1986	Medikamentöse Therapie nach Koronarinterventionen. 2009 , 5, 273-283		
1985	Leitfaden Herzkatheter. 2009 ,		2
1984	Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?. 2009 , 9 Suppl 1, 13-7		1
1983	Update on oral antiplatelet therapy: principles, problems and promises. 2009 , 5, 247-58		23
1982	Prasugrel: A New Thienopyridine Inhibitor. 2009 , 22, 158-165		1
1981	P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. 2009 , 30, 1964-77		283
1980	Adventures in cardiovascular research. 2009 , 120, 170-80		18
1979	Clinical pharmacology of antithrombotic drugs in coronary artery disease. 2009 , 3, 465-78		3
1978	Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. 2009 , 39, 218-26		31
1977	Effective platelet inhibition by aspirin and clopidogrel: where are we now?. 2009 , 95, 850-8		5
1976	Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. 2009 , 12, 141-53		2

1975	Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke. 2009 , 10, 1883-94	9
1974	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. 2009 , 119, 1873-82	701
1973	The Role of Aspirin in Cardiovascular Disease Prevention in Women. 2009 , 3, 123-134	2
1972	A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. 2009 , 37, 2145-52	99
1971	Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. 2009 , 2, 285-93	67
1970	G-protein-coupled receptors as signaling targets for antiplatelet therapy. 2009 , 29, 449-57	90
1969	Clopidogrel versus prasugrel: times are changing, but not for everyone. 2009 , 29, 1393-6	6
1968	Prasugrel: a critical comparison with clopidogrel. 2009 , 29, 1441-51	24
1967	Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. 2009 , 29, 812-21	10
1966	Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. 2009 , 29, 1089-102	62
1965	New P2Y12 blockers. 2009 , 7 Suppl 1, 262-5	31
1964	Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. 2009 , 103, 5-10	237
1963	Emerging insights on antiplatelet therapy. Introduction. 2009 , 103, 1A-3A	1
1962	Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. 2009 , 103, 11A-19A	18
1961	Advances in antiplatelet therapy: agents in clinical development. 2009 , 103, 40A-51A	75
1960	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. 2009 , 104, 1078-82	61
1959	Tug of war. 2009 , 104, 1C-3C	1
1958	Definition, incidence, correlates, and clinical impact of "nuisance" bleeding in patients undergoing drug-eluting stent implantation. 2009 , 104, 30C-3C	5

1957	Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. 2009 , 104, 34C-8C	40
1956	Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction. 2009 , 104, 39C-43C	0
1955	Platelet-directed therapies and coronary artery bypass grafting. 2009 , 104, 44C-8C	10
1954	Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?. 2009 , 104, 4C-8C	
1953	Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. 2009 , 104, 9C-15C	74
1952	Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits. 2009 , 104, 16C-21C	15
1951	Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. 2009 , 104, 22C-9C	17
1950	Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies. 2009 , 104, 60C-3C	9
1949	Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention?. 2009 , 104, 1505-10	3
1948	[What's new on antithrombotics?]. 2009 , 58, 230-5	1
1947	Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. 2009 , 10, 36-44	24
1946	Effects of prasugrel, a novel P2Y ₁₂ inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. 2009 , 612, 29-34	14
1945	Association of level of kidney function and platelet aggregation in acute myocardial infarction. 2009 , 54, 262-9	1
1944	Antiagregaci3n plaquetaria en la enfermedad arterial oclusiva: clopidogrel. 2009 , 23, 37-43	
1943	Actualizaci3n en cardiopat3a isqu3mica. 2009 , 9, 80-91	
1942	Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. 2009 , 73, 1-14	28
1941	Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. 2009 , 73, 488-96	41
1940	Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. 2009 , 74, 579-97	24

1939	Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. 2010 , 75, 128-34	5
1938	Cardiac enzyme elevations after apparently successful percutaneous interventions are a marker of extensive coronary artery disease and complex stenoses. 2009 , 74, 823-5	
1937	2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association	46
1936	The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. 2009 , 2, 534-41	115
1935	Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. 2009 , 2, 1095-101	38
1934	Clinical trials update from the European Society of Cardiology congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE. 2009 , 23, 25-9	1
1933	Oral antiplatelet therapy for acute and chronic management of NSTEMI/ACS: residual ischemic risk and opportunities for improvement. 2009 , 23, 489-99	5
1932	Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. 2009 , 27, 300-6	5
1931	Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. 2009 , 28, 513-4	1
1930	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. 2009 , 11, 22-32	11
1929	Antiplatelet therapy for prevention of recurrent stroke. 2009 , 11, 452-9	9
1928	Kommentar zu den Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des akuten Koronarsyndroms ohne ST-Strecken-Hebung (NSTEMI/ACS). 2009 , 3, 81-100	11
1927	IQWiG gegen den Rest der Welt. 2009 , 3, 207-210	
1926	Konsensuspapier âPeri- und postinterventioneller Schlaganfall bei Herzkatheterprozedurenâ 2009 , 3, 375-387	2
1925	Optimales prâhospitales Management des ST-Strecken-Hebungsinfarktes. 2009 , 4, 142-149	
1924	Thienopyridine therapy and risk for cardiovascular events in secondary prevention. 2009 , 11, 364-70	3
1923	Advances in percutaneous coronary intervention. 2009 , 11, 245-51	4
1922	Medical therapy in acute coronary syndromes: which medicines and at what doses?. 2009 , 11, 267-75	2

1921	Prasugrel versus clopidogrel in primary PCI: considerations of the TRITON-TIMI 38 substudy. 2009 , 11, 323-4	
1920	Perioperative handling of antiplatelet therapy: watching the two sides of the coin. 2009 , 4, 275-6	3
1919	Prasugrel: Clinical development and therapeutic application. 2009 , 26, 999-1011	8
1918	[Perioperative management of patients with coronary stents in non-cardiac surgery]. 2009 , 58, 971-85	30
1917	[Prasugrel or clopidogrel in patients with coronary intervention]. 2009 , 50, 1293-6	
1916	[Consensus paper on peri-interventional and postinterventional stroke during cardiac catheter procedures]. 2009 , 80, 1205-6, 1208-15	6
1915	The Italian Horizon Scanning Project. 2009 , 65, 775-81	17
1914	[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. 2009 , 38, 320-8	1
1913	Clopidogrel resistance "Live" - the risk of stent thrombosis should be evaluated before procedures. 2009 , 7, 6	5
1912	Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. 2009 , 34, 585-94	61
1911	New antithrombotic drugs. 2009 , 86, 139-46	77
1910	In Brief. 2009 , 8, 182-183	
1909	Prasugrel. 2009 , 8, 449-50	18
1908	Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 2009 , 22, 378-84	4
1907	AZD6140 and bleeding: towards safer antiplatelet therapy?. 2009 , 63, 537-9	1
1906	Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. 2009 , 63, 667-70	11
1905	New antiplatelet drugs: beyond aspirin and clopidogrel. 2009 , 63, 776-89	17
1904	CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. 2009 , 7, 1747-9	25

1903	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. 2009 , 7, 1612-8	28
1902	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. 2009 , 23, 1-9	6
1901	Variability of response to antiplatelet therapy: what should we do next?. 2009 , 23, 19-22	1
1900	Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. 2009 , 23, 411-7	16
1899	Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. 2009 , 2, 861-70	38
1898	Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. 2009 , 2, 1074-82	68
1897	The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 2009 , 2, 1102-4	1
1896	Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. 2009 , 2, 1279-85	29
1895	In search of a better platelet ADP-receptor blocker. 2009 , 17, 188-9	1
1894	Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. 2009 , 17, 195-8	10
1893	Clopidogrel response variability: current status and future directions. 2009 , 102, 7-14	91
1892	HORIZONS trial: a step forward for primary percutaneous coronary intervention. 2009 , 7, 125-9	1
1891	Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. 2009 , 39, 836-43	53
1890	Genomics of cardiovascular disease. 2009 , 76, 613-23	9
1889	High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis. 2009 , 4, 119-124	2
1888	Treatment. 2009 , 146-217	
1887	New antiplatelet agents: why they are needed. 2009 , 20, 733-8	26
1886	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. 2009 , 123, 597-603	65

1885	Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 2009 , 123, 419-28	3
1884	Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. 2009 , 124, 318-22	33
1883	Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. 2009 , 124, 6-13	39
1882	Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. 2009 , 124, 678-82	2
1881	Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. 2009 , 124, 565-71	67
1880	Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?. 2009 , 133, 8-17	6
1879	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. 2009 , 157, 369-74	63
1878	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary Intervention in Acute Coronary Lesions (PRACTICAL) Trial. 2009 , 157, 60.e1-9	15
1877	Facts and controversies of aspirin and clopidogrel therapy. 2009 , 157, 412-22	17
1876	Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. 2009 , 157, 562.e1-9	69
1875	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. 2009 , 157, 620-4.e2	79
1874	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. 2009 , 157, 818-24, 824.e1	92
1873	Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. 2009 , 158, e21-6	25
1872	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. 2009 , 158, 335-341.e3	157
1871	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. 2009 , 158, 327-334.e4	111
1870	Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". 2009 , 158, 925-32	59
1869	Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. 2009 , 122, 407-8	35
1868	Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. 2009 , 58, 1101-9	370

1867	Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention. 2009 , 53, 1176-81	13
1866	Combining antiplatelet and anticoagulant therapies. 2009 , 54, 95-109	121
1865	Antithrombotics in acute coronary syndromes. 2009 , 54, 969-84	44
1864	Pharmacogenetics in cardiovascular antithrombotic therapy. 2009 , 54, 1041-57	81
1863	The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. 2009 , 54, 678-85	94
1862	Women are like men ... Sometimes. 2009 , 54, 1946-8	3
1861	Hunting for the "sweet spot" in P2Y12 receptor blockade. 2009 , 54, 1447-9	3
1860	Atherogenesis and atherothrombosis--focus on diabetes mellitus. 2009 , 23, 291-303	35
1859	Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. 2009 , 154, 309-13	11
1858	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2 4753
1857	Platelet function testing in clinical practice: are we ready for prime time?. 2009 , 62, 113-6	1
1856	Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2009 , 69, 1707-26	16
1855	Clopidogrel resistance: pharmacokinetic or pharmacogenetic?. 2009 , 49, 506-12	25
1854	Acute Coronary Syndromes: Diagnosis and Management, Part I. 2009 , 84, 917-938	244
1853	Management of anticoagulation before and after gastrointestinal endoscopy. 2009 , 104, 3085-97; quiz 3098	46
1852	Target populations and relevant therapeutic end points to further improve outcomes in NSTEMACS patients. 2009 , 5, 27-41	
1851	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. 2009 , 6, 273-82	73
1850	Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. 2009 , 26, 781-90	11

1849	[Study of variability in response to aspirin and clopidogrel: clinical and/or biological resistance?]. 2009 , 67, 265-71	1
1848	Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?. 2009 , 6, 737-8	18
1847	Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. 2009 , 4, 115-26	58
1846	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. 2009 , 7, 361-9	11
1845	Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. 2009 , 2, 357-60	0
1844	An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. 2009 , 22, 51-6	14
1843	Oral antiplatelet therapy in the secondary prevention of atherothrombotic events. 2009 , 9, 197-209	6
1842	Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. 2009 , 9, 213-29	26
1841	Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. 2009 , 25, 1821-9	24
1840	Drug-eluting stents for acute myocardial infarction. 2009 , 10, 19-34	2
1839	Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 2009 , 157, 599-605	302
1838	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. 2009 , 25, 683-9	63
1837	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. 2009 , 373, 309-17	755
1836	Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 2009 , 373, 919-28	276
1835	Ischaemia versus bleeding: the art of clinical decision-making. 2009 , 373, 695-6	12
1834	Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. 2009 , 373, 723-31	834
1833	Prasugrel STEMI subgroup analysis. 2009 , 373, 1845-6; author reply 1846-8	4
1832	Prasugrel STEMI subgroup analysis. 2009 , 373, 1846; author reply 1846-8	2

1831	Prasugrel STEMI subgroup analysis. 2009 , 373, 1846; author reply 1846-8	1
1830	Prasugrel STEMI subgroup analysis âAuthors' reply. 2009 , 373, 1846-1848	2
1829	Threshold for starting antiretroviral therapy: should there be one?. 2009 , 373, 1848	
1828	Department of Error. 2009 , 373, 1848	
1827	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. 2009 , 374, 787-95	102
1826	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. 2009 , 374, 989-997	531
1825	Otamixaban in acute coronary syndromes. 2009 , 374, 762-4	7
1824	Risk of combining PPIs with thienopyridines: fact or fiction?. 2009 , 374, 952-954	34
1823	Underestimation of the effect of bleeding in clinical trials. 2009 , 374, 1145; author reply 1145-6	2
1822	S�ndrome coronario agudo sin elevaci�n del segmento ST. Evaluaci�n inicial. Validaci�n del diagn�stico y estratificaci�n del riesgo. Tratamiento inicial. Estrategia invasiva. Modalidades de revascularizaci�n. 2009 , 10, 2465-2473	
1821	[Update on ischemic heart disease]. 2009 , 62 Suppl 1, 80-91	1
1820	Pruebas de funci�n plaquetaria en la pr�ctica cl�nica: �estamos preparados para que pasen a la primera l�nea?. 2009 , 62, 113-116	4
1819	2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association	1029
1818	Cytochrome p-450 polymorphisms and response to clopidogrel. <i>New England Journal of Medicine</i> , 2009 , 360, 354-62	59.2 1874
1817	Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. 2009 , 23, 375-88	43
1816	Prasugrel: a novel platelet ADP P2Y receptor antagonist. 2009 , 27, 194-8	5
1815	Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. 2009 , 27, 259-74	256
1814	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. 2009 , 10, 1799-817	81

1813	P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. 2009 , 43, 64-76	10
1812	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. 2009 , 5, 989-1004	62
1811	Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. 2009 , 25, 1477-90	7
1810	Management of patients with high gastrointestinal risk on antiplatelet therapy. 2009 , 38, 289-303	18
1809	Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. 2009 , 84, 149-160	16
1808	Diagnosis and treatment of acquired coronary artery disease in adults. 2009 , 85, 364-5	1
1807	Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. 2009 , 16, 244-55	9
1806	Clinical implications and management of bleeding events in patients with acute coronary syndromes. 2009 , 10, 677-86	7
1805	Current world literature. 2009 , 24, 95-101	
1804	A new generation of antiplatelet agents. 2009 , 24, 307-12	7
1803	New P2Y12 antagonists. 2009 , 16, 371-7	23
1802	Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. 2009 , 20, 207-13	12
1801	Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. 2009 , 8, 12-9	3
1800	Late prasugrel benefit in STEMI patients?. 2009 , 16, 469-70	1
1799	Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond. 2009 , 16, 451-8	10
1798	Clopidogrel in the management of acute coronary syndromes: indications, results, obstacles. 2009 , 8, 49-54	1
1797	ST-Segment-Elevation Myocardial Infarction. 2009 , 79-121	
1796	Introduction. 2009 , 11, G2-G3	

1795	Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. 2009 , 2009, 404-406	
1794	Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. 2009 , 2009, 313-315	
1793	Benefits for specific subpopulations in TRITON-TIMI 38. 2009 , 11, G18-G24	1
1792	Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A). 2009 , 40, 3883-5	1
1791	Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. 2009 , 48, 1725-30	46
1790	Management of patients with aspirin and clopidogrel impaired response. 2009 , 1, 31-40	2
1789	Unstable Angina and Non-ST-Elevation Myocardial Infarction. 2009 , 37-78	
1788	Impaired response to aspirin and clopidogrel: how do we treat?. 2009 , 1, 29-30	
1787	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. 2009 , 2009, 315-317	
1786	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. 2009 , 30, 1753-63	206
1785	Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?. 2009 , 24, 88-94	5
1784	Anesthetic concerns for patients with coagulopathy. 2010 , 23, 400-5	5
1783	Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. 2010 , 25, 305-11	5
1782	Impact of age on outcomes of percutaneous coronary intervention in acute coronary syndromes patients. 2010 , 2, 319-325	1
1781	Stent thrombosis and duration of dual antiplatelet therapy. 2010 , 16, 4052-63	6
1780	Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. 2010 , 23, 65-72	7
1779	Research Highlights. 2010 , 11, 1687-1690	
1778	Emerging P2Y12 receptor antagonists: role in coronary artery disease. 2010 , 8, 93-101	3

1777	Challenges and promises of developing thrombin receptor antagonists. 2010 , 5, 162-70	7
1776	Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. 2010 , 38, 50-8	2
1775	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. 2010 , 2010, 397-399	
1774	Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. 2010 , 31, 2816-21	52
1773	Early and aggressive treatment of patients with ST-segment elevation myocardial infarction: deciphering recent clinical trials and the timing of optimal platelet inhibition. 2010 , 12, D24-D35	
1772	Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome. 2010 , 38, 109-11	
1771	Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. 2010 , 2010, 507-508	
1770	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. 2010 , 2010, 72-75	
1769	Perioperative stent thrombosis. 2010 , 2, 821-828	
1768	The role of antiplatelet therapy in the secondary prevention of coronary artery disease. 2010 , 25, 321-8	12
1767	Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'Anna Tirofiban Safety study. 2010 , 11, 250-9	16
1766	Clopidogrel resistance. 2010 , 17, 210-5	19
1765	Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. 2010 , 55, 585-94	7
1764	Management of patients with coronary stents in the ICU. 2010 , 16, 426-31	1
1763	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. 2010 , 21, 46-52	26
1762	Early antiplatelet therapy in coronary artery bypass grafting: a calculated benefit. 2010 , 5, 317-25	2
1761	High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. 2010 , 2, 619-621	
1760	Evidence for interaction between clopidogrel and proton-pump inhibitors. 2010 , 67, 605-606	0

1759	Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. 2010 , 74, 679-85	35
1758	General Preoperative Considerations and Preparation of the Patient for Surgery. 2010 , 129-171	
1757	Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. 2010 , 103, 71-82	97
1756	Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. 2010 , 303, 2156-64	218
1755	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. 2010 , CD002130	16
1754	Basic principles of platelet biology and clinical implications. 2010 , 74, 597-607	200
1753	Noncardiac surgery following percutaneous coronary intervention. 2010 , 2, 841-850	
1752	Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. 2010 , 2, 705-718	2
1751	A new era for antiplatelet therapy in patients with acute coronary syndrome. 2010 , 340, 407-11	7
1750	Acute coronary syndrome update for hospitalists. 2010 , 5 Suppl 4, S15-21	0
1749	Prasugrel, a new platelet inhibitor. 2010 , 77, 315-23	1
1748	Antiplatelets and anticoagulants. 2010 , 33, 388-9	
1747	Mechanism of action and clinical development of platelet thrombin receptor antagonists. 2010 , 8, 1191-200	18
1746	Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. 2010 , 50, 126-42	296
1745	Factors associated with clopidogrel nonresponsiveness. 2010 , 6, 195-210	9
1744	[Comments on the 2010 guidelines on cardiopulmonary resuscitation of the European Resuscitation Council]. 2010 , 59, 1105-23	21
1743	[Update: oral platelet inhibitors in cardiology]. 2010 , 51, 533-8	0
1742	[Switching from clopidogrel hydrogen sulfate to clopidogrel besylate. Impaired antiplatelet effect in patients with ischemic stroke]. 2010 , 81, 992-7	

1741	The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. 2010 , 66, 127-35	50
1740	Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. 2010 , 66, 487-96	154
1739	Intracranial stenting in atherosclerotic disease-recent results and challenges to face. 2010 , 52, 633-44	6
1738	The state of periprocedural antiplatelet therapy after recent trials. 2010 , 3, 571-83	34
1737	Initiales Management des akuten Koronarsyndroms. 2010 , 13, 621-634	5
1736	Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. 2010 , 160, 30-8	8
1735	Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 2010 , 3, 704-16	14
1734	Reevaluation of clopidogrel: let the data speak for themselves. 2010 , 30, 299-306	1
1733	Drug-eluting stents in the elderly. 2010 , 12, 76-83	6
1732	Antithrombotics in acute coronary syndromes: updates from the past year. 2010 , 12, 84-99	1
1731	Is There a Role for Platelet Function Testing for Patients on Chronic Dual Antiplatelet Therapy?. 2010 , 4, 327-331	
1730	Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI). 2010 , 4, 84-92	11
1729	Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. 2010 , 4, 107-123	6
1728	Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. 2010 , 4, 239-248	0
1727	Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). 2010 , 4, 353-364	1
1726	PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes. 2010 , 12, 283-5	1
1725	What goes into a major acute coronary syndrome trial and what will future trials look like?. 2010 , 12, 348-55	2
1724	State of the art of new P2Y12 antagonists. 2010 , 5, 385-91	16

1723	Antiplatelet and anticoagulant therapies in acute coronary syndromes. 2010 , 24, 61-70	7
1722	Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. 2010 , 24, 325-30	4
1721	Secondary prevention strategies for coronary heart disease. 2010 , 29, 8-24	20
1720	Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. 2010 , 29, 516-28	4
1719	Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. 2010 , 30, 200-9	5
1718	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. 2010 , 30, 127-32	20
1717	Poor response to clopidogrel: current and future options for its management. 2010 , 30, 319-31	47
1716	Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis. 2010 , 30, 452-8	13
1715	Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?. 2010 , 30, 332-9	9
1714	Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes?. 2010 , 30, 240-9	1
1713	Prasugrel : une avancè dans la prise en charge du syndrome coronaire aigu trait`par angioplastie. 2010 , 21, 9	
1712	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. 2010 , 9, 273-84	72
1711	Nuevas evidencias y directrices en antiagregaci3n y anticoagulaci3n en s3ndrome coronario agudo e intervencionismo coronario percut3neo. 2010 , 10, 21C-29C	
1710	Nuevos antiagregantes en el s3ndrome coronario agudo. El futuro es hoy. 2010 , 10, 12-22	0
1709	¿Qu`dicen las gu3as?. 2010 , 10, 29-33	
1708	Novedades en el tratamiento antitromb3tico en intervencionismo coronario. 2010 , 10, 34-41	
1707	Tratamiento antitromb3tico en diabeticos con s3ndrome coronario agudo. 2010 , 10, 42-48	
1706	El ticagrelor, un nuevo antiagregante, mejora los resultados cardiovasculares en pacientes con s3ndrome coronario agudo. 2010 , 17, 720	

1705	[The recommendations regarding non-ST segment elevation acute coronary syndrome have been reviewed. SEMICYUC. Spanish Society for Intensive Medicine, Critical Care and Coronary Units]. 2010 , 34, 22-45	4
1704	Percutaneous coronary intervention. 2010 , 38, 438-445	2
1703	Understanding Clopidogrel's Interaction with CYP2C19 Inhibitors. 2010 , 6, 715-720	1
1702	Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. 2010 , 125, 249-59	28
1701	Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. 2010 , 127, 95-107	15
1700	Recent therapeutic approaches to platelet activation in coronary artery disease. 2010 , 127, 108-20	17
1699	Genetic causes of clopidogrel nonresponsiveness: which ones really count?. 2010 , 30, 265-74	29
1698	Clopidogrel and proton pump inhibitors: between a rock and a hard place. 2010 , 30, 762-5	3
1697	Impact of acute coronary syndromes on two-year clinical outcomes in patients with unprotected left main coronary artery stenosis treated with drug-eluting stents. 2010 , 105, 174-8	10
1696	Aspirin--a drug whose time has gone?. 2010 , 105, 577-8	0
1695	Mortality in the TRITON trial: update from the FDA prasugrel action package. 2010 , 105, 1356-7	10
1694	Mortality in the TRITON trial: update from the FDA prasugrel action package. 2010 , 106, 293-4	2
1693	Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. 2010 , 106, 1208-11	47
1692	[ST-segment elevation acute coronary syndromes: Prehospital management strategies]. 2010 , 59, 329-34	
1691	[Bleeding risk in ST-segment elevation myocardial infarction]. 2010 , 59, 356-61	1
1690	[Antithrombotic treatments in acute coronary syndromes with persistent ST-segment elevation]. 2010 , 59, 335-43	
1689	Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 2010 , 90, 1040-51	22
1688	Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. 2010 , 32, 365-79	40

1687	Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. 2010 , 32, 2265-81	19
1686	Antiplatelet agents in acute coronary syndromes. 2010 , 35, 123-70	13
1685	Regional anaesthesia and anticoagulation. 2010 , 24, 121-31	18
1684	Patients under anti-platelet therapy. 2010 , 24, 41-50	12
1683	[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials]. 2010 , 59 Suppl 2, S47-55	
1682	Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. 2010 , 14, 2371-80	4
1681	Meeting the unmet needs in anticoagulant therapy. 2010 , 85, 1-28	61
1680	Oral antiplatelet therapy in PCI patients. 2010 , 75 Suppl 1, S7-14	1
1679	European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. 2010 , 81, 1353-63	54
1678	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. 2010 , 81 Suppl 1, e175-212	39
1677	Perioperative management of patients with drug-eluting stents. 2010 , 3, 131-42	59
1676	2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology. 2010 , 3, 256-8	4
1675	Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. 2010 , 3, 648-56	33
1674	Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. 2010 , 3, 731-41	67
1673	Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. 2010 , 3, 806-11	60
1672	Percutaneous coronary intervention in native vessels with angiographically visible thrombus temporal trends and impact of drug-eluting stents. 2010 , 3, 937-46	2
1671	The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. 2010 , 3, 1209-19	30
1670	Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTEMI-ACS) in older patients. 2010 , 51, 129-34	1

1669	Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. 2010 , 8, 9	19
1668	Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. 2010 , 8, 37-42	55
1667	The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 2010 , 8, 43-53	81
1666	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. 2010 , 8, 250-6	274
1665	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. 2010 , 8, 641-50	11
1664	Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. 2010 , 8, 1678-84	76
1663	Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. 2010 , 8, 1903-11	13
1662	Outcome after primary angioplasty for acute myocardial infarction in old age. 2010 , 58, 2236-7; author reply 2237	
1661	Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. 2010 , 159, 502-17	83
1660	Management of acute coronary syndromes from a gender perspective. 2010 , 24, 719-28	2
1659	Defining patients at high risk for gastrointestinal hemorrhage after drug-eluting stent placement: a cost utility analysis. 2010 , 23, 179-87	1
1658	Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. 2010 , 70, 65-77	115
1657	Antiplatelet drug interactions. 2010 , 268, 516-29	26
1656	Proton pump inhibitor and clopidogrel interaction: fact or fiction?. 2010 , 105, 34-41	87
1655	Antiplatelet therapies for the treatment of cardiovascular disease. 2010 , 9, 154-69	271
1654	Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. 2010 , 9, 435-45	82
1653	Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. 2010 , 54, 16-41	120
1652	Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. 2010 , 6, 419-29	12

1651	. 2010,	11
1650	Determinants to optimize response to clopidogrel in acute coronary syndrome. 2010, 3, 33-50	13
1649	The role of prasugrel in prevention of CV events. 2010, 5, 526-528	
1648	Antiplatelet Therapy. 2010, 452-469	
1647	Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. 2010, 1, 197-219	26
1646	Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. 2010, 6, 963-77	19
1645	Thienopyridine antiplatelet agents: focus on prasugrel. 2010, 25, 241-57	4
1644	High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. 2010, 104, 279-86	40
1643	Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. 2010, 4, 203-20	6
1642	Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. 2010, 17, 156-64	93
1641	Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. 2010, 5, e10130	38
1640	Anticoagulation after anterior myocardial infarction and the risk of stroke. 2010, 5, e12150	15
1639	Pre-procedural platelet reactivity after clopidogrel loading in Korean patients undergoing scheduled percutaneous coronary intervention. 2010, 17, 1122-31	12
1638	New drugs approved in 2009. 2010, 23, 175-83	1
1637	The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?. 2010, 2, 155-62	4
1636	High-dose clopidogrel, prasugrel or ticagrelor: trying to unravel a skein into a ball. 2010, 1, 13	
1635	Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. 2011, 2, 7-19	5
1634	Ticagrelor: a novel oral antiplatelet agent. 2010, 25, 745-55	

1633	ADP-receptor blockade: A case for personalised pharmacotherapy?. 2010 , 103, 496-506	14
1632	Application of platelet function testing to the bedside. 2010 , 103, 29-33	20
1631	Emerging antiplatelet agents, differential pharmacology, and clinical utility. 2010 , 1, 79-91	6
1630	Impact of genetic polymorphisms on clinical response to antithrombotics. 2010 , 3, 87-99	6
1629	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. 2010 , 103, 205-12	24
1628	The TRITON versus PLATO trials: differences beyond platelet inhibition. 2010 , 103, 259-61	18
1627	Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. 2010 , 103, 1210-7	69
1626	Impact of race and gender on antithrombotic therapy. 2010 , 104, 471-84	55
1625	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. 2010 , 2, 233-40	8
1624	Prasugrel. 2010 , 45, 54-66	
1623	Problems of contemporary antiplatelet treatment. 2010 , 1, 21-29	
1622	New drug update: 2010. 2010 , 25, 608-10, 614-6, 618-22 passim	
1621	Medical Management of Unstable Angina and Non-àST Segment Elevation Myocardial Infarction. 2010 , 183-195	
1620	Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. 2010 , 15, 326-37	14
1619	Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. 2010 , 304, 1839-40	29
1618	Combination antithrombotic therapies. 2010 , 121, 569-83	96
1617	Clopidogrel in acute coronary syndrome: implications of recent study findings. 2010 , 8, 1215-29	2
1616	Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. 2010 , 122, 2680-7	149

1615	Ticagrelor to prevent restenosis: new drug for an old hypothesis?. 2010 , 30, 2320-2	6
1614	New P2Y(12) inhibitors. 2010 , 121, 171-9	169
1613	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. 2010 , 122, S422-65	74
1612	Minimizing the risks of anticoagulants and platelet inhibitors. 2010 , 121, 1960-70	26
1611	Platelet function testing and risk of bleeding complications. 2010 , 103, 1128-35	79
1610	ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology/American College of Gastroenterology/American Heart Association Task Force on Practice Guidelines. 2010 , 103, 1128-35	180
1609	Special issue of the 10th EFCC Continuous Postgraduate Course in Clinical Chemistry: "New trends in classification, diagnosis and management of thrombophilia", October 2010, Dubrovnik, Croatia. 2010 , 48 Suppl 1, S1	1
1608	Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. 2010 , 122, 445-8	29
1607	Implementing genotype-guided antithrombotic therapy. 2010 , 6, 409-24	19
1606	A 43-year-old man with angina, elevated troponin, and lateral ST depression: management of acute coronary syndromes. 2010 , 303, 54-63	
1605	SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. 2010 , 30, 2143-9	39
1604	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. 2010 , 31, 227-35	56
1603	An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. 2010 , 9, 192-8	7
1602	Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. 2010 , 38, 898-904	29
1601	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. 2010 , 121, 2575-83	173
1600	Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. 2010 , 9, 199-202	2
1599	Perspectives on the 2009 focused updates on the management of ST-segment elevation myocardial infarction and percutaneous intervention. 2010 , 9, 126-33	1
1598	Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. 2010 , 31, 1206-10	73

1597	Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. 2010 , 121, 5-7	9
1596	ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. 2010 , 122, 537-57	150
1595	Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?". 2010 , 3, 3-5	5
1594	Periprocedural myocardial infarction: prevalence, prognosis, and prevention. 2010 , 3, 602-10	114
1593	Closing discussion. 2010 , 7, 611-616	
1592	Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. 2010 , 2010, 595934	11
1591	Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. 2010 , 2, 37ra45	16
1590	Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. 2010 , 4, 117-28	16
1589	Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. 2010 , 30, 2385-91	41
1588	Personalized healthcare in clotting disorders. 2010 , 7, 65-73	
1587	Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. 2010 , 121, 71-9	115
1586	Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome. 2010 , 23, 324-34	1
1585	Pharmacogenetics guided anticoagulation. 2010 , 48 Suppl 1, S119-27	
1584	Prasugrel. 2010 , 122, 394-403	92
1583	Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes. 2010 , 50, 904-13	4
1582	Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. 2010 , 6, 393-407	18
1581	Clinical Guide to Primary Angioplasty. 2010 ,	
1580	ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. 2010 , 105, 2533-49	131

1579	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2010 , 31, 1311-8	179
1578	The future of antiplatelet therapy in cardiovascular disease. 2010 , 61, 49-61	18
1577	Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. 2010 , 7, 461-7	33
1576	Platelet function tests for the monitoring of P2Y12 inhibitors. 2010 , 4, 251-65	2
1575	Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization. 2010 , 31, 530-41	60
1574	Aptamers: the emerging class of future anticoagulation for vascular disease. 2010 , 8, 503-7	7
1573	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk. 2010 , 67, S7-17	3
1572	Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. 2010 , 16, 170-6	16
1571	Fine-tuning therapy for acute coronary syndromes. <i>New England Journal of Medicine</i> , 2010 , 363, 976-7	59.2 5
1570	Clopidogrel hypersensitivity: clinical challenges and options for management. 2010 , 3, 553-61	10
1569	Nonresponders to clopidogrel: pharmacokinetics and interactions involved. 2010 , 11, 2391-403	9
1568	Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. 2010 , 107, 18605-10	38
1567	Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. 2010 , 3, 450-9	16
1566	Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 2010 , 121, 43-51	100
1565	Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. 2010 , 122, S787-817	191
1564	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 2010 , 304, 1821-30	778
1563	Role of ticagrelor in clopidogrel nonresponders: resistance is futile?. 2010 , 121, 1169-71	17
1562	Management of non-ST-segment elevation acute coronary syndromes. Introduction. 2010 , 67, S3-6; quiz S29-31	

1561	What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. 2010 , 103, 367-77	8
1560	Eugene Braunwald: escaping death and prolonging lives [part 1] Interview by Ruth Williams. 2010 , 106, 1668-71	4
1559	Platelet thrombin receptor antagonism and atherothrombosis. 2010 , 31, 17-28	183
1558	Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. 2010 , 7, 274-88	5
1557	Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention. 2010 , 30, 45-54	5
1556	The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. 2010 , 3, 277-83; discussion 283	8
1555	How Does One Diagnose and Manage Acute Myocardial Ischemia in the Intensive Care Unit?. 2010 , 303-310	
1554	Prasugrel as a potential cancer promoter: review of the unpublished data. 2010 , 170, 1078-80	24
1553	Update on the clinical development of cangrelor. 2010 , 8, 1069-77	19
1552	Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome. 2010 , 12, D14-D23	1
1551	Acute coronary syndromes: assessing risk and choosing optimal pharmacological regimens for a superior outcome. 2010 , 12, D4-D13	2
1550	Interpreting the TRITON results in light of the event adjudication process. 2010 , 115, 89-90	
1549	Advances in antiplatelet therapy for stroke prevention: the new P2Y12 antagonists. 2010 , 11, 380-91	5
1548	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. 2010 , 31, 1337-43	33
1547	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. 2010 , 27, 999-1015	348
1546	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. 2010 , 31, 667-75	53
1545	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. 2010 , 31, 1677-1681	46
1544	2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts. 2010 , 33, e85-9	1

- 1543 Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. **2010**, 117, 231-3 12
- 1542 [Concomitant use of platelet aggregation inhibitors and proton pump inhibitors (PPIs): Position paper of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society of Cardiology (DGK)]. **2010**, 48, 1156-63 11
- 1541 [Platelet inhibition with prasugrel]. **2010**, 135, 1542-6
- 1540 Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. **2010**, 31, 2971-3 7
- 1539 Antithrombotische Therapie der koronaren Herzerkrankung. **2010**, 6, 247-256
- 1538 Aktuelle Aspekte der modernen interventionellen Koronartherapie. **2010**, 6, 317-334
- 1537 Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. **2010**, 4, 421-34 4
- 1536 Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. **2010**, 38, 38-43 2
- 1535 Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials. **2010**, 7, 124-5 6
- 1534 Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review. **2010**, 341, c5707 69
- 1533 Latest drug developments in the field of cardiovascular disease. **2010**, 19, e100-5 13
- 1532 Decision-making: stenting in acute myocardial infarction. **2010**, 6, 301-14 1
- 1531 Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. **2010**, 44, 524-37 35
- 1530 Benefits of and safety concerns associated with drug-eluting coronary stents. **2010**, 8, 449-70 20
- 1529 Thrombocardiology: an update. **2010**, 8, 331-3
- 1528 Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world setting. **2010**, 38, 7-17 8
- 1527 Emerging oral antiplatelet therapies for acute coronary syndromes. **2010**, 38, 29-37 1
- 1526 Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. **2010**, 122, 198-200 1

1525	Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance. 2010 , 170, 1010-2	7
1524	Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348. 2010 , 11, 1015-22	12
1523	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. 2010 , 6, 445-53	47
1522	The PLATO trial: do you believe in magic?. 2010 , 31, 764-7	17
1521	Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. 2010 , 1207, 134-42	3
1520	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2010 , 363, 930-42	59.2 582
1519	Haro sur les plaquettesâ€ 2010 , 23, S4-S5	
1518	Prasugrel. 2010 , 4, 43-50	0
1517	Que peut-on faire pour amliorer le pronostic des syndromes coronariens aigus?. 2010 , 2010, 31-34	
1516	Prasugrelâ€ en pratique dans lâ€urgence, pour quels patients ?. 2010 , 23, S48-S51	
1515	Antiagrâ€ants plaquettaires et syndrome coronaire aigu : comment choisir le traitement de demain ? : 2e partie. 2010 , 2010, 29-31	
1514	Triton, quel bnfice clinique ?. 2010 , 23, S44-S47	
1513	Quelle place pour lâ€aspirine en prvention cardiovasculaire primaire chez le diabtique en 2010?. 2010 , 4, 456-466	
1512	Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery: a review of current treatment strategies. 2010 , 24, 562-72	3
1511	TRITON-TIMI 38 : quel bnfice clinique dans la prise en charge des SCA traitâ€s par angioplastie ?. 2010 , 2010, S20-S23	
1510	Peripheral artery disease: current insight into the disease and its diagnosis and management. 2010 , 85, 678-92	190
1509	Une nouvelle gnfation de thifopyridine, quel bnfice clinique? Pour le cardiologue. 2010 , 23, S22-S25	
1508	Le prasugrel en pratique : quel patient ? Comment ? Quelle durâ€e ?. 2010 , 2010, S24-S26	

- 1507 Quelle prise en charge pour vos patients présentant un syndrome coronarien aigu (SCA). **2010**, 23, S38-S43
- 1506 Médicaments antiplaquettaires: anciennes et nouvelles thérapies. **2010**, 24, 154-163
- 1505 Conclusion générale. **2010**, 2010, 31 2
- 1504 La pharmacothérapie pour améliorer les résultats des pontages sous-inguinaux : Examen des stratégies actuelles de traitement. **2010**, 24, 612-624
- 1503 Antiplatelet medications: old and emerging therapies. **2010**, 24, 140-8 2
- 1502 La maîtrise des plaquettes, un vrai défi?. **2010**, 23, S6-S10
- 1501 Antiagrégants plaquettaires et syndrome coronaire aigu : comment choisir le traitement de demain ? : 1re partie. **2010**, 2010, 27-29
- 1500 Une nouvelle génération de thiénopyridine, quel bénéfice clinique? Pour l'urgentiste. **2010**, 23, S17-S21
- 1499 A comparison of the metabolism of clopidogrel and prasugrel. **2010**, 6, 1417-24 14
- 1498 Cardiac Complications and Management. 355-376
- 1497 Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. **2010**, 26, 2077-85 8
- 1496 The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. **2010**, 103, 379-86 14
- 1495 Trial and error. How to avoid commonly encountered limitations of published clinical trials. **2010**, 55, 415-27 87
- 1494 Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. **2010**, 55, 1139-46 169
- 1493 Eptifibatid is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). **2010**, 56, 470-5 51
- 1492 The glycoprotein IIb/IIIa inhibitor wars: an update. **2010**, 56, 476-8 8
- 1491 Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. **2010**, 56, 1017-23 148
- 1490 Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. **2010**, 55, 2435-45 403

1489	The case for routine genotyping in dual-antiplatelet therapy. 2010 , 56, 109-11	35
1488	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. 2010 , 56, 919-33	913
1487	Antithrombotic therapy in the elderly. 2010 , 56, 1683-92	98
1486	ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2010 , 56, 321-41	250
1485	Antiplatelet therapy and coronary artery bypass graft surgery a fallow land. 2010 , 56, 2003-5	5
1484	Coronary stents: current status. 2010 , 56, S1-42	371
1483	New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. 2010 , 56, 1542-51	86
1482	Stent thrombosis. 2010 , 56, 1357-65	312
1481	Another step on the road to tailored antiplatelet therapy. 2010 , 56, 1637-8	1
1480	ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. 2010 , 56, 2051-68	164
1479	Clopidogrel resistance: what's new?. 2010 , 103, 349-53	11
1478	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. 2010 , 103, 13-28	232
1477	Clopidogrel with or without omeprazole in coronary artery disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1909-17	59.2 827
1476	Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. 2010 , 49, 777-98	49
1475	Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 2010 , 70, 1771-83	23
1474	Hemorrhage in patients with acute coronary syndrome: from annoying observation to major challenge. 2010 , 63, 1-4	
1473	Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. 2010 , 63, 60-76	17
1472	Comment gfer les nouveaux antithrombotiques dans la pfiode pfiopfatoire ?. 2010 , 35, 79-80	

1471	Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. 2010 , 183, 2128-36	56
1470	Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. 2010 , 15, 6-16	9
1469	Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. 2010 , 31, 2601-13	124
1468	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. 2010 , 31, 3006-16	317
1467	Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. 2010 , 26, 871-8	19
1466	Antiplatelet therapy and vascular disease: an update. 2010 , 4, 249-75	15
1465	Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?. 2010 , 138, 212-3	9
1464	The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions. 2010 , 144, 79-82	4
1463	Adiponectin/C-reactive protein interplay in healthy individuals and in patients with coronary artery disease. 2010 , 144, 82-4	
1462	The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. 2010 , 142, 187-92	44
1461	Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHEsus trial. 2010 , 143, 309-16	15
1460	Update of cerebral vascular disease: issues for the primary care physician. 2010 , 56, 40-71	10
1459	Aspirin as antiplatelet agent in diabetes. PROS-. 2010 , 21, 149-53	7
1458	New anticoagulants in internal medicine: an update. 2010 , 21, 466-7	2
1457	New antiplatelet agents in acute coronary syndromes (ACS): an update. 2010 , 21, 465-6	1
1456	Composition of thrombi in late drug-eluting stent thrombosis versus de novo acute myocardial infarction. 2010 , 126, 254-7	17
1455	Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. 2010 , 125, 110-1	39
1454	Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. 2010 , 125, e190-6	25

1453	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. 2010 , 126, e147-9	36
1452	Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. 2010 , 126, e334-8	22
1451	The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. 2010 , 126, e339-43	8
1450	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. 2010 , 126, e400-2	23
1449	Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). 2010 , 159, 284-291.e1	56
1448	Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. 2010 , 159, 508-517.e1	19
1447	Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. 2010 , 159, 871-5	40
1446	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. 2010 , 159, 891-898.e1	35
1445	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) 2010 , 160, 75-79	65
1444	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. 2010 , 160, 16-22.e1	109
1443	Novel antiplatelet therapy. 2010 , 160, 595-604	16
1442	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stents or bare metal stents. 2010 , 160, 103-109	132
1441	Appropriate cardiac cath lab activation: optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. 2010 , 160, 995-1003, 1003.e1-8	102
1440	Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials: Author reply. 2010 , 160, e49	
1439	Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials. 2010 , 160, e47; author reply e49	
1438	Evaluation and management of special subgroups after primary percutaneous coronary intervention. 2010 , 160, S22-7	9
1437	Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. 2010 , 160, S36-41	6
1436	Public sensationalism and clinical trials: how to address the challenges of science?. 2010 , 123, 481-3	7

1435	Proton pump inhibitors and clopidogrel. 2010 , 28, 169-76	1
1434	Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?. 2010 , 28, 139-46	19
1433	Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. 2010 , 3, 17-26	79
1432	Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. 2010 , 103, 213-23	125
1431	A risk score to predict bleeding in patients with acute coronary syndromes. 2010 , 55, 2556-66	479
1430	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. 2010 , 376, 1312-9	473
1429	Hemorragia en pacientes con síndromes coronarios agudos: de un hallazgo molesto a un reto importante. 2010 , 63, 1-4	3
1428	Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. 2010 , 63, 60-76	58
1427	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 2010 , 375, 283-93	531
1426	Ticagrelor in ACS: redefining a new standard of care?. 2010 , 375, 263-5	14
1425	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. 2010 , 376, 1320-8	598
1424	Response to antiplatelet treatment: from genes to outcome. 2010 , 376, 1278-81	14
1423	Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-1H-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propanamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. 2010 , 53, 18-36	36
1422	New antithrombotic agents--insights from clinical trials. 2010 , 7, 498-509	36
1421	Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. 2010 , 104, 609-17	53
1420	The year in cardiothoracic and vascular anesthesia: selected highlights from 2009. 2010 , 24, 7-17	7
1419	Progress in platelet medicine: focus on stent thrombosis and drug resistance. 2010 , 24, 722-7	11
1418	Anticoagulants, Antiplatelets, and Thrombolytics. 2010 ,	2

1417	Guidelines on myocardial revascularization. 2010 , 31, 2501-55	2070
1416	Antiplatelet Agents. 2010 , 409-476	2
1415	Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. 2010 , CD004815	35
1414	Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data. 2010 , 61, 215-31	6
1413	Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. 2010 , 152, 337-45	161
1412	Analisi di costo-efficacia di prasugrel rispetto a clopidogrel nel trattamento di pazienti con sindrome coronarica acuta e intervento di angioplastica per via percutanea programmato. 2010 , 3, 55-63	
1411	Limitations of current therapies to prevent thrombosis: a need for novel strategies. 2010 , 6, 305-15	24
1410	Emerging drugs for acute myocardial infarction. 2010 , 15, 87-105	0
1409	The comparative safety of bare-metal and drug-eluting intracoronary stents. 2010 , 7, 611-24	4
1408	Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. 2010 , 10, 49-61	3
1407	Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. 2010 , 122, 1056-67	280
1406	Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated?. 2010 , 122, 1049-52	22
1405	New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor. 2010 , 11, 325-9	3
1404	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. 2010 , 17, 121-130	2
1403	Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease. 2010 , 10, 115-24	3
1402	Comparative effectiveness research and personalized medicine: catalyzing or colliding?. 2010 , 28, 905-13	32
1401	Platelet P2Y ₁₂ receptor inhibition: an update on clinical drug development. 2010 , 10, 217-26	18
1400	Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. 2010 , 21, 1-10	11

1399	Ticagrelor for the treatment of arterial thrombosis. 2010 , 11, 2251-9	21
1398	Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. 2010 , 21, 503-7	27
1397	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. 2011 , 9, 999-1014	3
1396	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. 2011 , 32, 1345-61	793
1395	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. 2011 , 20, 119-33	11
1394	Bleeding complications of unfractionated heparin. 2011 , 10, 77-84	9
1393	Valutazione economica di ticagrelor vs Clopidogrel nel trattamento di pazienti con sindrome coronarica acuta. 2011 , 13, 53-64	
1392	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. 2011 , 32, 1605-13	158
1391	Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy. 2011 , 6, 353-69	
1390	Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. 2011 , 43, 531-44	32
1389	Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. 2011 , 22, 521-9	4
1388	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. 2011 , 124, 2458-73	1087
1387	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 2011 , 32, 2541-54	142
1386	Diagnostic Molecular Pathology in Practice. 2011 ,	1
1385	Peripheral artery disease. Part 2: medical and endovascular treatment. 2011 , 8, 429-41	31
1384	Ticagrelor. 2011 , 5, 55-62	
1383	Recomendações sobre revascularização do miocárdio. 2011 , 30, 951-1005	
1382	Analytical method development and validation of prasugrel in bulk and its pharmaceutical formulation using the RP-HPLC method. 2011 , 2, 173-7	4

1381	Le rapport bénéfice-risque des nouveaux agents antiagrégants plaquettaires. 2011 , 2011, 27-31	3
1380	Gestion péfiofatoire des nouveaux antiplaquettaires. 2011 , 15, 188-193	
1379	Antiplatelet therapy in coronary heart disease prevention. 2011 , 29, 71-85	7
1378	Acute coronary syndrome: new and evolving therapies. 2011 , 23, 559-71	0
1377	Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. 2011 , 57, 399-408	103
1376	Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. 2011 , 57, 672-84	370
1375	Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. 2011 , 57, 1190-9	48
1374	Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. 2011 , 57, 685-7	28
1373	Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. 2011 , 57, 1445-54	42
1372	2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2011 , 57, 1920-59	297
1371	Cardiac care for older adults. Time for a new paradigm. 2011 , 57, 1801-10	157
1370	High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. 2011 , 58, 467-73	181
1369	Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. 2011 , 58, 1445-54	40
1368	Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty Myocardial Infarction) randomized study. 2011 , 58, 1592-9	97
1367	Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. 2011 , 58, 1945-54	339
1366	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 58, 2550-2583	99
1365	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 58, e44-122	1703
1364	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. 2011 , 58, 2584-2614	59

1363	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. 2011 , 58, e123-210	531
1362	On-clopidogrel platelet reactivity: a target in sight?. 2011 , 58, 1955-7	
1361	Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. 2011 , 58, 2263-9	40
1360	AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. 2011 , 58, 2432-46	574
1359	Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. 2011 , 4, 905-12	16
1358	Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. 2011 , 4, 1119-28	28
1357	Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?. 2011 , 4, 1129-32	10
1356	Platelets and endothelium: two key players in percutaneous coronary intervention. 2011 , 104, 601-3	2
1355	Vorapaxar: a novel protease-activated receptor-1 inhibitor. 2011 , 20, 1445-53	13
1354	The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 2011 , 105, 760-2	24
1353	Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. 2011 , 106, 219-26	37
1352	Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. 2011 , 12, 1285-95	35
1351	Resistance to Antiplatelet Therapy. 2011 , 1	
1350	Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. 2011 , 106, 572-84	152
1349	Managing adverse effects and drug-drug interactions of antiplatelet agents. 2011 , 8, 592-600	15
1348	Triple antiplatelet therapy in acute coronary syndromes. 2011 , 71, 1703-19	11
1347	Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLoPIDogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. 2011 , 9, 3	64
1346	Ticagrelor: from concept to clinical evaluation. 2011 , 5, 53-62	7

1345	Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. 2011 , 28, 119-29		6
1344	The evolution of antiplatelet therapy in cardiovascular disease. 2011 , 8, 547-59		70
1343	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,		
1342	Thrombose de stent. 2011 , 2011, 31-34		
1341	Cost-effectiveness of oral antiplatelet agents--current and future perspectives. 2011 , 8, 580-91		7
1340	Genetic determinants of on-clopidogrel high platelet reactivity. 2011 , 22, 399-407		44
1339	Antiplatelet therapy in acute coronary syndromes. 2011 , 16, 24-42		8
1338	Syndromes coronariens aigus : prise en charge thfapeutique en urgence. 2011 , 1		1
1337	Le ticagrelor dans les syndromes coronaires aigus : rŕultats de lâEtude PLATO. 2011 , 1		1
1336	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
1335	A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. 2011 , 161, 650-656.e1		22
1334	Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. 2011 , 161, 450-61		25
1333	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. 2011 , 161, 605-10		28
1332	Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. 2011 , 161, 832-41		16
1331	Response to the letter regarding the article "Do East Asians have different hypercoagulable states compared with Western population?" 2011 , 162, e21-e22		
1330	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. 2011 , 162, 363-71		7
1329	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. 2011 , 162, 518-26.e5		42
1328	Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. 2011 , 162, 844-51		47

1327	Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. 2011 , 162, 1062-1068.e5	39
1326	Upstream treatment of acute coronary syndrome in the ED. 2011 , 29, 446-56	
1325	ED to catheterization laboratory: a roundtable integrating trials with practice. 2011 , 29, 1203-16	
1324	The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. 2011 , 27 Suppl A, S1-59	85
1323	The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. 2011 , 27, 208-21	39
1322	Prasugrel as an alternative for clopidogrel-associated neutropenia. 2011 , 27, 869.e9-11	6
1321	Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS. 2011 , 27 Suppl A, S387-401	24
1320	Heart failure and non-ST-segment elevation myocardial infarction: a review for a widespread situation. 2011 , 22, 533-40	4
1319	Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖARI) and the Working	146
1318	Focused clinical review: periprocedural management of antiplatelet therapy in patients with coronary stents. 2011 , 20, 438-45	7
1317	2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. 2011 , 20, 487-502	83
1316	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. 2011 , 150, 325-31	119
1315	Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. 2011 , 146, 242-3	2
1314	How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?. 2011 , 149, 265-267	9
1313	Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. 2011 , 149, 267-269	
1312	Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. 2011 , 54, e1-31	439
1311	[New era in antiplatelet therapy based on results from recent clinical trials]. 2011 , 137, 504-8	3
1310	Current concepts on coronary revascularization in diabetic patients. 2011 , 32, 2748-57	67

1309	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 2011 , 32, 2999-3054	2614
1308	High platelet reactivity and clinical outcome - fact and fiction. 2011 , 106, 191-202	50
1307	Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. 2011 , 128, 458-62	13
1306	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. 2011 , 128, e130-6	26
1305	Consensus on: Screening and therapy of coronary heart disease in diabetic patients. 2011 , 21, 757-64	3
1304	Cardiovascular disease in the elderly. 2011 , 64, 697-712	45
1303	Resistance to anti-platelet agents. 2011 , 127 Suppl 3, S61-3	23
1302	Antithrombotic therapy in ST-segment elevation myocardial infarction. 2011 , 12, 213-23	2
1301	Platelet function testing in clinical diagnostics. 2011 , 31, 79-87	23
1300	Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. 2011 , 90, 328-32	346
1299	Therapeutic strategies in patients with chronic stable coronary artery disease. 2011 , 29, e23-30	3
1298	Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. 2011 , 29, e100-11	23
1297	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. 2011 , 32, 838-46	161
1296	Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. 2011 , 72, 683-96	37
1295	Prasugrel – step ahead in antiplatelet therapy. 2011 , 1, 17-24	
1294	Cardiovascular drug therapy in the elderly: benefits and challenges. 2011 , 8, 13-28	109
1293	P2Y12 receptor in platelet activation. 2011 , 22, 56-60	59
1292	[Antiplatelet agents and proton pump inhibitors. How can the risk-benefit balance be optimized in patients at risk for cardiovascular disease and gastrointestinal bleeding?]. 2011 , 34, 478-91	

1291	Evaluation and management of shock States: hypovolemic, distributive, and cardiogenic shock. 2011 , 24, 44-60	21
1290	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. 2011 , 7, 381-402	10
1289	Cardiovascular Disease in the Elderly. 2011 , 64, 697-712	3
1288	Tratamiento extrahospitalario y en Urgencias del síndrome coronario agudo sin elevación del segmento ST. 2011 , 10, 5903-5906	
1287	No One-Size-Fits-All. 2011 , 1	
1286	High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. 2011 , 105, 927-30	5
1285	Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. 2011 , 106, 211-8	30
1284	Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. 2011 , 106, 1149-57	26
1283	Platelet function variability and non-genetic causes. 2011 , 105 Suppl 1, S60-6	26
1282	Intervenção coronária percutânea em idosos: impacto da faixa etária mais avançada (> 80 Anos) no perfil clínico e nos resultados imediatos. 2011 , 19, 400-404	2
1281	Coronary Artery Disease in the Elderly. 2011 ,	
1280	Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. 2011 , 105 Suppl 1, S67-74	25
1279	Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society. 2011 , 1, 20-55	
1278	Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. 2011 , 7, 445-59	9
1277	[New approaches and indications for the analysis of platelet function in cardiology]. 2011 , 31, 73-6	2
1276	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. 2011 , 106, 141-8	13
1275	Critical appraisal of ticagrelor in the management of acute coronary syndrome. 2011 , 7, 473-88	17
1274	Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes. 2011 , 6, 31-42	3

1273	Clinical evidence of interaction between clopidogrel and proton pump inhibitors. 2011 , 3, 153-64	5
1272	Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. 2011 , 105 Suppl 1, S75-81	29
1271	Antiplatelet combinations for prevention of atherothrombotic events. 2011 , 7, 23-30	5
1270	Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. 2011 , 105, 752-9	41
1269	Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. 2011 , 106, 248-52	23
1268	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. 2011 , 106, 253-62	32
1267	Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. 2011 , 106, 1-19	110
1266	Big science for small cells: systems approaches for platelets. 2011 , 12, 1859-70	3
1265	New anti-thrombotic drugs for stroke prevention. 2011 , 9, 723-32	7
1264	Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. 2011 , 26, 275-8	4
1263	Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. 2011 , 112, 777-99	15
1262	Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. 2011 , 39, 2346-53	14
1261	Direct vasoactive properties of thienopyridine-derived nitrosothiols. 2011 , 58, 550-8	8
1260	Joint ESC/EACTS guidelines on myocardial revascularization. 2011 , 12, 264-7	10
1259	Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. 2011 , 58, 329-34	11
1258	Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients: 2011 update. 2011 , 12, 860-7	
1257	Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention. 2011 , 39, 436-42	18
1256	The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. 2011 , 57, 86-93	62

1255	The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. 2011 , 57, 317-24	11
1254	Antiplatelet therapy in acute coronary syndromes: implications for nursing practice. 2011 , 26, 239-49	2
1253	Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. 2011 , 171, 1948-9	38
1252	Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. 2011 , 12, 1831-5	7
1251	Anti-inflammatory treatment of acute coronary syndromes. 2011 , 17, 4172-89	14
1250	Advances in antiplatelet therapy. 2011 , 2011, 62-9	27
1249	Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y ₁₂ inhibition and thrombin receptor antagonists. 2011 , 12, 1805-12	4
1248	CYP2C19*2allele: guiding medication choice after percutaneous coronary intervention. 2011 , 3, 1-4	
1247	Role of ticagrelor in the treatment of coronary artery disease. 2011 , 1, 429-437	
1246	The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. 2011 , 1, 1155-1165	
1245	Antiplatelet therapy in elderly patients. 2011 , 7, 311-320	2
1244	Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. 2011 , 112, 292-318	150
1243	Is prasugrel more effective than clopidogrel at preventing future cardiac events?. 2011 , 24, 52, 55	
1242	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. 2011 , 2011, 277-279	
1241	Antiplaquettaires: pharmacologie. 2011 , 6, 1-11	
1240	The platelet P2Y ₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. 2011 , 117, 2102-12	142
1239	Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. 2011 , 75, 2105-12	15
1238	Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in the pharmacoinvasive management of ST elevation MI. 2011 , 3, 17-21	

1237	Role of platelets and antiplatelet therapy in cardiovascular disease. 2011 , 18, 431-42	41
1236	The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel. 2011 , 90, 27-9	7
1235	Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. 2011 , 12, 29-36	16
1234	[Not Available]. 2011 , 153, 37-43	
1233	Ticagrelor for acute coronary syndrome?. 2011 , 49, 66-8	1
1232	Antiplatelet therapy: thrombin receptor antagonists. 2011 , 72, 658-71	25
1231	Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. 2011 , 72, 604-18	12
1230	Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. 2011 , 72, 619-33	135
1229	Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. 2011 , 72, 697-706	33
1228	Anti-platelet therapy: ADP receptor antagonists. 2011 , 72, 647-57	71
1227	Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes. 2011 , 41, 1268-74	9
1226	Oral antiplatelet agents in ACS: from pharmacology to clinical differences. 2011 , 25, 564-71	8
1225	How do we manage patients treated with antithrombotic therapy in the perioperative interval. 2011 , 51, 2066-77	5
1224	Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. 2011 , 9, 1705-12	115
1223	Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. 2011 , 9, 2050-6	25
1222	Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. 2011 , 9, 2133-42	68
1221	Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. 2011 , 9, 2361-70	100
1220	Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. 2011 , 9, 2379-85	68

1219	Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion. 2011 , 24, 119-36	2
1218	Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. 2011 , 24, 199-207	6
1217	Low stent thrombosis risk with the XIENCE V [®] Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials. 2011 , 24, 326-41	8
1216	Fresh from the pipeline. Ticagrelor. 2011 , 10, 255-6	26
1215	Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. 2011 , 89, 229-33	31
1214	The role of antiplatelets in hypertension and diabetes mellitus. 2011 , 13, 305-13	7
1213	Atherothrombosis and the role of antiplatelet therapy. 2011 , 9 Suppl 1, 325-32	16
1212	Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. 2011 , 60, 1584-9	22
1211	Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future. 2011 , 60, 1497-9	2
1210	A Prescriber's Guides to Oral Antiplatelet Therapy. 2011 , 7, 847-852	
1209	Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. 2011 , 58, 6-17	12
1208	Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. 2011 , 129, 267-89	41
1207	Patient blood management during cardiac surgery: do we have enough evidence for clinical practice?. 2011 , 142, 249.e1-32	49
1206	¿Los nuevos antagonistas del receptor P2Y12 pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. 2011 , 11, 14-19	
1205	Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS. 2011 , 11, 27-32	
1204	Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. 2011 , 33, 425-42	7
1203	Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. 2011 , 33, 1057-68	11
1202	Myocardial revascularization by percutaneous coronary intervention: past, present, and the future. 2011 , 36, 375-401	10

1201	Direct formation of thienopyridine-derived nitrosothiols--just add nitrite!. 2011 , 670, 534-40	7
1200	Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. 2011 , 107, 198-203	49
1199	An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. 2011 , 107, 495-500	54
1198	Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). 2011 , 107, 995-1000	83
1197	Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTC registry). 2011 , 107, 1441-6	6
1196	Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients \geq 5 years of age (from the FAST-MI registry). 2011 , 108, 755-9	5
1195	Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. 2011 , 108, 905-11	53
1194	Cardiovascular medications and risk of cancer. 2011 , 108, 1045-51	7
1193	Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. 2011 , 108, 760-5	35
1192	Comparison of platelet reactivity and clopidogrel response in patients \geq 5 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. 2011 , 108, 1411-6	17
1191	Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. 2011 , 108, 1710-3	31
1190	[Decreasing incidence of stent thrombosis]. 2011 , 60, 338-46	
1189	Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. 2011 , 12, 94-8	7
1188	Ticagrelor: new antiplatelet for prevention of thrombotic events. 2011 , 12, 14-16	
1187	Clopidogrel in acute coronary syndromes: where are we now?. 2011 , 105, 766-73	5
1186	No free lunches: balancing bleeding and efficacy with ticagrelor. 2011 , 32, 2919-21	1
1185	Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. 2011 , 34, 332-8	37
1184	Antiplatelet agents for the treatment and prevention of atherothrombosis. 2011 , 32, 2922-32	160

1183	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2013 , 82, E266-355	81
1182	The pharmacogenetics of antiplatelet agents: towards personalized therapy?. 2011 , 8, 560-71	32
1181	Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. 2011 , 19, 279-84	21
1180	Age related issues in reperfusion of myocardial infarction. 2011 , 25, 139-48	10
1179	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. 2011 , 33, 3-9	17
1178	Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. 2011 , 32, 64-71	30
1177	Antiplatelet agents in cardiovascular disease. 2011 , 31, 306-9	14
1176	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. 2011 , 32, 242-66	2
1175	Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. 2011 , 32, 328-33	9
1174	Genetic determinants of platelet response to clopidogrel. 2011 , 32, 459-66	56
1173	The P2Y ₁₂ receptor as a target of antithrombotic drugs. 2011 , 7, 325-32	12
1172	P2 receptors and platelet function. 2011 , 7, 293-303	97
1171	Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?. 2011 , 123, 468-76	5
1170	Deutsch-Österreichische S3-Leitlinie âInfarktbedingter kardiogener Schock âDiagnose, Monitoring und Therapieâ 2011 , 48, 291-344	5
1169	Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. 2011 , 100, 907-14	7
1168	Akutes Koronarsyndrom. 2011 , 14, 8-14	
1167	[Cardial target-organ damage in diabetes]. 2011 , 52, 505-17	
1166	[Therapy strategies for acute coronary syndrome and after coronary interventions. Antiplatelet agents and anticoagulants]. 2011 , 52, 1292-300	

1165	[Coronary stent thrombosis: what's new in 2011?]. 2011 , 36, 241-53	2
1164	Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with Balloon angioplasty). 2011 , 4, 14-23	94
1163	Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. 2011 , 4, 365-80	43
1162	Considerations Regarding Antiplatelet Therapy in the Elderly. 2011 , 5, 86-95	
1161	Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. 2011 , 5, 411-435	11
1160	Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 *2/*2 genotype. 2011 , 26, 79-82	2
1159	Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. 2011 , 26, 783-90	271
1158	Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation). 2011 , 13, 314-20	1
1157	P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?. 2011 , 13, 320-6	1
1156	Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease. 2011 , 13, 287-95	7
1155	Personalized antiplatelet therapy: review of the latest clinical evidence. 2011 , 13, 296-302	14
1154	Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?. 2011 , 13, 303-11	1
1153	Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists. 2011 , 13, 439-50	1
1152	Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel. 2011 , 11, 52-60	10
1151	Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. 2011 , 8, 12	34
1150	Novel agents for anti-platelet therapy. 2011 , 4, 44	24
1149	Prasugrel. 2011 , 28, 235-236	
1148	An automated database case definition for serious bleeding related to oral anticoagulant use. 2011 , 20, 560-6	230

1147	Emerging clinical applications in cardiovascular pharmacogenomics. 2011 , 3, 206-15	6
1146	Subgroup analyses of clinical effectiveness to support health technology assessments. 2011 , 10, 532-8	15
1145	Gestion pharmaceutique des antiplaquettaires et des anticoagulants. 2011 , 2011, 17-19	
1144	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. 2011 , 25, 123-9	31
1143	Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. 2011 , 4, 381-91	40
1142	Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. 2011 , 4, 403-10	101
1141	The optimal pharmacological formula for percutaneous coronary intervention. 2011 , 12, 1075-86	
1140	Antiplatelet options for secondary prevention in acute coronary syndromes. 2011 , 9, 1403-15	1
1139	Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists. 2011 , 5, 43-51	10
1138	Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association. 2011 , 7, 163-7	
1137	Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes. 2011 , 123, 79-90	5
1136	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. 2011 , 5, 9-30	2
1135	Acquired disorders of platelet function. 2011 , 2011, 391-6	65
1134	Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. 2011 , 43, 445-61	191
1133	Was bringen die neuen PII-Funktionshemmer beim akuten Koronarsyndrom?. 2011 , 7, 227-242	
1132	[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease]. 2011 , 136, 1433-7	
1131	Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. 2011 , 39, 32-40	10
1130	Notfallbehandlung bei akutem Koronarsyndrom nach aktuellen Leitlinien. 2011 , 6, 65-80	

1129	Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?. 2011 , 5, 1-3	2
1128	Non-interventional management of acute coronary syndromes. 2011 , 342, d3263	
1127	Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. 2011 , 342, d3488	4
1126	Concomitant use of thrombocyte aggregation inhibitors and proton pump inhibitors (PPIs). 2011 , 49, 395-402	0
1125	[Update on anti-platelet therapy]. 2011 , 136, 1260-4	
1124	Role of platelet function testing in clinical practice: current concepts and future perspectives. 2011 , 12, 1836-47	9
1123	Beyond platelet functional testing: value in the aggregate. 2011 , 5, 5-8	6
1122	[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. 2011 , 136, 782-5	
1121	Clinical applications of bivalirudin in the cardiac catheterization laboratory. 2011 , 16, 140-9	8
1120	Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. 2011 , 27, 2117-22	4
1119	Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. 2011 , 51, 321-32	28
1118	Prevention and management of TURP-related hemorrhage. 2011 , 8, 504-14	21
1117	Rivaroxaban in the contemporary treatment of acute coronary syndromes. 2011 , 20, 849-57	3
1116	Modification of the VerifyNow [®] P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. 2011 , 22, 619-25	15
1115	Unravelling the benefit against the risk of long-term dual antiplatelet therapy. 2011 , 26 Suppl 1, S22-30	3
1114	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. 2011 , 123, 1745-56	193
1113	Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations. 2011 , 27, 558-64	12
1112	Does Platelet Function Testing Predict Bleeding?-Pro. 2011 , 10, 133-135	

1111	New insights in antiplatelet therapy for patients with ischemic stroke. 2011 , 17, 255-62	1
1110	Updating the chest pain algorithm: incorporating new evidence on emerging antiplatelet agents. 2011 , 10, 9-16	4
1109	Dual antiplatelet therapy duration: what are the drivers?. 2011 , 26 Suppl 1, S4-14	5
1108	Non-ST-segment elevation acute coronary syndrome: impact of nursing care on optimal outcomes. 2011 , 22, 113-24	
1107	Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention: benefits versus risks. 2011 , 26 Suppl 1, S1-3	
1106	Use of prasugrel in a patient with clopidogrel hypersensitivity. 2011 , 45, e54	13
1105	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. 2011 , 104, 561-9	32
1104	Triple antithrombotic therapy after coronary stenting: why expert opinion is necessary. 2011 , 4, 410-2	
1103	Thromboelastography-platelet mapping expanding in non-cardiac surgery. 2011 , 39, 1085; author reply 1085-6	3
1102	Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. 2011 , 31, 51-63	0
1101	Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel. 2011 , 123, 73-9	5
1100	Platelet biology and implications for antiplatelet therapy in atherothrombotic disease. 2011 , 17, 371-80	7
1099	Recent developments in the use of antiplatelet agents to prevent cardiovascular events. 2011 , 7, 403-13	5
1098	Review: Antiplatelet drugs: what comes next?. 2011 , 17, 9-26	17
1097	Thienopyridines in Acute Coronary Syndrome. 2011 , 45, 207-17	1
1096	Defining the optimal dose of aspirin and clopidogrel in acute coronary syndromes. Evaluation of dose comparisons of clopidogrel and aspirin in acute coronary syndromes [N Engl J Med 2010;363:930-42. 2011 , 12, 149-51	1
1095	Variability of clopidogrel response in patients with type 2 diabetes mellitus. 2011 , 8, 245-53	27
1094	Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel. 2011 , 39, 208-14	11

1093	Inhibitors of the platelet thrombin receptor: will they live up to their promises?. 2011 , 123, 1833-5	16
1092	Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding. 2011 , 338, 22-30	24
1091	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 123, 2022-60	267
1090	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. 2011 , 123, 2736-47	2467
1089	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 124, e652-735	487
1088	Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of ThrombinâCoronary Artery Disease Trial. 2011 , 123, 1854-63	112
1087	An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 2011 , 305, 1136-7	31
1086	Nouvelles stratâgies anticoagulantes et antiagrâgantes : âtat des lieux et proposition de prise en charge en chirurgie orale. 2011 , 277-288	
1085	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 124, 2574-609	389
1084	Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. 2011 , 123, 1891-9	170
1083	P2Yââreceptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. 2011 , 45, 1151-6	8
1082	Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. 2011 , 4, 162-70	41
1081	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. 2011 , 4, 522-34	88
1080	When stable becomes unstable: the perils of impersonal medicine. 2011 , 123, 335-41	0
1079	Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. 2011 , 124, 2320-8	26
1078	Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. 2011 , 4, 448-58	25
1077	Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). 2011 , 123, 2681-9	134
1076	Reply to Cattano and Pivalizza. 2011 , 39, 1085-1086	

1075	Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2011 , 32, 2989-97	61
1074	Optimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7. 2011 , 4, 95-103	12
1073	Platelet-mediated thrombosis and drug-eluting stents. 2011 , 4, 629-37	4
1072	Ticagrelor: a novel reversible oral antiplatelet agent. 2011 , 19, 95-100	38
1071	Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. 2011 , 32, 2970-88	71
1070	Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years. 2011 , 42, 1722-9	21
1069	Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. 2011 , 32, 2358-64	14
1068	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. 2011 , 32, 2256-65	34
1067	How much of the world do you need for meaningful clinical trials?. 2011 , 32, 3057-8	
1066	P2Y receptors in health and disease. 2011 , 61, 417-39	24
1065	Percutaneous coronary intervention in the elderly. 2011 , 8, 79-90	51
1064	The intestine as an important contributor to prasugrel active metabolite formation in vivo. 2011 , 39, 565-70	9
1063	Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 2011 , 4, 474-80	35
1062	Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. 2011 , 4, 505-13; discussion 513	14
1061	Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON. 2011 , 123, 1709-12	13
1060	Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUTY Trial. 2011 , 4, 577-84	34
1059	Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. 2011 , 106, 272-7	63
1058	Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. 2011 , 9, 697-710	9

1057	Assessment of oral antithrombotic therapy by platelet function testing. 2011 , 8, 572-9	18
1056	Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. 2011 , 9, 1295-303	
1055	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. 2011 , 16, 203-33	1
1054	Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. 2011 , 123, 451-6	32
1053	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 124, e574-651	1039
1052	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 2011 , 32, 2781-9	411
1051	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 124, 2610-42	345
1050	Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. 2011 , 343, d4588	190
1049	Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. 2011 , 4, 514-21; discussion 521	18
1048	Diabetes and antiplatelet therapy in acute coronary syndrome. 2011 , 123, 798-813	229
1047	Emerging antithrombotic drugs: A review. 2011 , 4, 138	
1046	Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms. 2011 , 68, 529-32	5
1045	Bleeding complications with the P2Y ₁₂ receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. 2011 , 32, 2933-44	262
1044	2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2012 , 126, 875-916	382
1043	Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. 2012 , 5, 296-304	6
1042	No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation. 2012 , 125, 471-3	8
1041	Republished education in heart: New P2Y ₁₂ inhibitors. 2012 , 88, 49-54	
1040	Current antiplatelet options for NSTEMI-ACS patients. 2012 , 105, 935-48	4

1039	Antiplatelet therapy in stroke prevention. 2012 , 47, 141-54	4
1038	Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. 2012 , 126, 83-91	63
1037	Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. 2012 , 2012, 909154	22
1036	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2 631
1035	Antithrombotic Therapy. 2012 , 171-177	
1034	Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 2012 , 5, 594-600	39
1033	Revascularization in multivessel CAD: a functional approach. 2012 , 9, 243-52	5
1032	Periprocedural antithrombotic strategies in acute ischemic stroke interventional therapy. 2012 , 79, S174-81	13
1031	Bleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?. 2012 , 40, 96-103	
1030	Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. 2012 , 5, 797-804	298
1029	Acute coronary syndrome and cardiogenic shock: management in the cardiac catheterization laboratory. 2012 , 50, 83-113	1
1028	Platelet protease-activated receptor antagonism in cardiovascular medicine. 2012 , 23, 375-9	2
1027	Management of non-ST-segment elevation acute coronary syndrome: comparison of the updated guidelines from North America and Europe. 2012 , 11, 62-73	
1026	Stent thrombosis in a clopidogrel nonresponder. 2012 , 35, 151-9	
1025	Protease-activated receptor-1 antagonists: focus on SCH 530348. 2012 , 19, 465-9	2
1024	Genetic determinants of response to cardiovascular drugs. 2012 , 27, 253-61	14
1023	A brief review of the past and future of platelet P2Y ₁₂ antagonist. 2012 , 23, 368-74	9
1022	Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. 2012 , 23, 523-7	4

1021	Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. 2012 , 19, 160-1	2
1020	Acute ST-elevation myocardial infarction. 2012 , 18, 417-23	4
1019	Management of the clotting system: a European perspective. 2012 , 25, 80-5	11
1018	2012 Oman Heart Association simplified guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. 2012 , 11, 139-46	3
1017	Projecting future drug expenditures--2012. 2012 , 69, 405-21	46
1016	Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia. 2012 , 108, 912-21	19
1015	Treatment algorithm in patients with NSTEMI and unstable angina. 2012 , 331-346	
1014	A regulator's view of comparative effectiveness research. 2012 , 9, 56-65	17
1013	[Modern treatment in acute coronary syndrome]. 2012 , 137, 722-5	1
1012	A review of the role of anticoagulation in the treatment of peripheral arterial disease. 2012 , 21, 187-94	25
1011	Clinical use of clopidogrel. 2012 , 18, 5224-39	23
1010	Using models to predict the future: what to do when the data run out?. 2012 , 91, 769-71	0
1009	Risk of bleeding related to antithrombotic treatment in cardiovascular disease. 2012 , 18, 5362-78	5
1008	Welche Thrombozytenaggregationshemmung ff.wen?. 2012 , 1, 44-48	
1007	The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: a critical appraisal. 2012 , 8, 26-30	14
1006	Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition. 2012 , 308, 1806-8	5
1005	Current status of clopidogrel pharmacogenomics. 2012 , 13, 1671-4	8
1004	Overcoming obstacles in pharmacogenomic strategies for antiplatelet drugs: are we RAPID enough?. 2012 , 13, 1105-8	2

1003	Acute coronary syndromes: identifying the appropriate patient for prasugrel. 2012 , 124, 16-28	1
1002	Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?. 2012 , 18, 5392-401	0
1001	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. 2012 , 3, 309-323	10
1000	Prästationäre Diagnostik und Therapie des Akuten Koronarsyndroms â[Kooperationen und Netzwerke zur gezielten Therapieeinleitung. 2012 , 41, 514-521	
999	Neue Thrombozytenaggregationshemmung bei Patienten mit akutem Koronarsyndrom â[Umbruch einer langjâhrigen antithrombozytären Praxis. 2012 , 41, 604-608	
998	Anti-inflammatory effects of anti-platelet treatment in atherosclerosis. 2012 , 18, 4311-25	15
997	Contemporary management of ST-segment elevation myocardial infarction. 2012 , 40, 224-31	
996	Perioperative antiplatelet management in patients with coronary artery stenting. 2012 , 40, 118-30	
995	[Platelet inhibitors and proton pump inhibitors: no more uncertainties?]. 2012 , 137, 799-801	0
994	Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. 2012 , 117, 929-33	45
993	The role of platelets in athero-thrombotic events. 2012 , 18, 5197-214	49
992	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. 2012 , 33, 2569-619	3978
991	Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. 2012 , 52, 789-97	44
990	Prasugrel resistance: fact or fiction. 2012 , 23, 83-90	28
989	Rapid P2Y12 inhibition: still an unmet medical need. 2012 , 5, 328-31	4
988	Prasugrel-induced rash. 2012 , 46, 1123-5	10
987	Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. 2012 , 5, 69-76, S1	17
986	Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. 2012 , 5, 523-31	8

985	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. 2012 , 8, 503-11	5
984	Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. 2012 , 23, 106-15	29
983	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. 2012 , 10, 1273-85	6
982	Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. 2012 , 28, 203-11	5
981	Cost-effectiveness of prasugrel in a US managed care population. 2012 , 15, 166-74	14
980	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. 2012 , 23, 537-51	16
979	Potential role of rivaroxaban in patients with acute coronary syndrome. 2012 , 6, 349-57	3
978	Antiplatelet therapy in ENT surgery: a review. 2012 , 126, 331-6	6
977	Current oral antiplatelets: focus update on prasugrel. 2012 , 25, 343-9	10
976	A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 2012 , 5, 336-46	66
975	Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. 2012 , 5, 261-9	196
974	Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel. 2012 , 98, 1617-9	6
973	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. 2012 , 8, 77-89	31
972	Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2012 , 40, 104-17	1
971	Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. 2012 , 47, 87-99	3
970	The role of the interventional cardiologist in selecting antiplatelet agents in acute coronary syndromes: a 10-question strategy. 2012 , 1, 170-6	1
969	Stability-Indicating LC Method for the Determination of Prasugrel Hydrochloride in Pharmaceutical Dosage Form. 2012 , 80, 379-91	6
968	Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction. 2012 , 2012, 683683	8

967	Long-term antiplatelet therapy: from clinical trials to clinical application. 2012 , 27, 347-54	1
966	Proton pump inhibitors: potential adverse effects. 2012 , 28, 615-20	93
965	Managing risk of complications at femoral vascular access sites in percutaneous coronary intervention. 2012 , 32, 16-29; quiz first page after 29	25
964	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 2012 , 125, 1276-87; discussion 1287	85
963	Development and clinical use of prasugrel and ticagrelor. 2012 , 18, 5240-60	16
962	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Society of Interventional Radiology, and Society of Thoracic Radiologists. 2012 , 125, 1234-1242	537
961	Overview of platelet functional testing methods and their controversial role in the management of a clopidogrel-treated patient. 2012 , 4, 537-547	
960	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. 2012 , 33, 1241-9	107
959	Toward a therapeutic window for antiplatelet therapy in the elderly. 2012 , 33, 1187-9	15
958	Road mapping ATLAS ACS 2: are we there yet?. 2012 , 33, 2510-2	3
957	Personalized antiplatelet therapy: state of the art. 2012 , 1,	
956	Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. 2012 , 10, 305-7	
955	Pharmacogenetics of the antiplatelet effect of aspirin. 2012 , 18, 5294-308	22
954	New oral anticoagulant agents after ACS. 2012 , 1, 87-93	4
953	Antiplatelet therapy for secondary prevention of acute coronary syndrome, transient ischemic attack, and noncardioembolic stroke in an era of cost containment. 2012 , 60, 792-800	2
952	Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. 2012 , 8, 181-91	2
951	Treatment of acute coronary syndrome: part 2: ST-segment elevation myocardial infarction. 2012 , 40, 1939-45	8
950	Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents. 2012 , 18, 850-60	3

949	Platelet function testing in atherothrombotic disease. 2012 , 18, 5379-91	28
948	Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. 2012 , 18, 5273-93	10
947	Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. 2012 , 18, 5344-61	47
946	Therapeutic potential and strategies against leukocyte-platelet interaction in atherosclerosis. 2012 , 10, 550-4	4
945	In the bivalirudin era, are we still looking for a potent antiplatelet agent?. 2012 , 10, 476-8	0
944	Novel antiplatelet therapy in acute coronary syndromes: what is new in the pipeline?. 2012 , 10, 606-18	1
943	Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. 2012 , 8, 239-49	9
942	Prevention and treatment of coronary distal embolization in the setting of acute myocardial infarction: pharmacologic approach. 2012 , 10, 463-7	6
941	Antiplatelet and anticoagulation strategies in the prevention and treatment of ischemic stroke. 2012 , 18, 5261-72	5
940	Counterpoint: should coagulopathy be repaired prior to central venous line insertion? No. 2012 , 141, 1142-1144	3
939	Contemporary use of glycoprotein IIb/IIIa inhibitors. 2012 , 107, 215-24	44
938	Mechanisms of platelet activation in acute coronary syndromes. 2012 , 10, 578-88	19
937	Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. 2012 , 13, 162-3	3
936	Simultaneous acute occlusion of right and anterior descending coronary arteries in acute myocardial infarction. 2012 , 13, 614-8	2
935	UA/NSTEMI: Are you following the latest guidelines?. 2012 , 42, 26-33; quiz 34	15
934	Coronary stent thrombosis in patients undergoing multidigit replantation. 2012 , 40, 285-9	1
933	Why does ticagrelor induce dyspnea?. 2012 , 108, 1031-6	61
932	The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG). 2012 ,	1

931	Miscellaneous topics. 447-452	
930	Hematological problems. 465-468	
929	Considerations for the use of proton-pump inhibitors in older adults. 2012 , 27, 114-20	14
928	Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e637S-e668S	371
927	Prévention secondaire chez le coronarien. 2012 , 7, 1-8	
926	Stratégie de prise en charge des syndromes coronariens aigus. 2012 , 7, 1-15	2
925	Factors influencing the outcomes of percutaneous coronary intervention in the stent era. 2012 , 4, 557-568	
924	Invasive management of the acute coronary syndromes. 2012 , 4, 279-285	
923	Is a higher loading dose of clopidogrel more effective during primary angioplasty for patients with STEMI?. 2012 , 4, 45-48	
922	Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. 2012 , 76, 2405-11	11
921	Options to overcome clopidogrel response variability. 2012 , 76, 287-92	21
920	Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. 2012 , 379, 923-931	171
919	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. 2012 , 379, 1705-11	285
918	Perioperative management of antiplatelet agents in patients undergoing cardiac surgery. 2012 , 26, 680-6	7
917	[Management of ST-elevation myocardial infarction in 2012]. 2012 , 61, 447-52	1
916	Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. 2012 , 10, 1946-9	9
915	Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. 2012 , 10, 2006-15	34
914	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. 2012 , 10, 1999-2005	102

913	2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. 2012 , 94, 1761-81	221
912	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2 570
911	Antiplatelet therapy following myocardial infarction in patients with diabetes. 2012 , 308, 921-2	10
910	Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke. 2012 , 125, 2821-3	19
909	Antiplatelets in acute coronary syndrome: personal perspectives. 2012 , 10, 1487-96	8
908	Thienopyridines and other ADP-receptor antagonists. 2012 , 165-98	17
907	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). 2012 , 125, 577-83	129
906	Modern antiplatelet agents in coronary artery disease. 2012 , 10, 1261-72	3
905	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses	1138
904	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. 2012 , 108, 12-20	6
903	Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 , 107, 1130-40	37
902	Personalizing antiplatelet therapy with clopidogrel. 2012 , 92, 476-85	11
901	Genetic considerations. 2012 , 47, 100-13	3
900	Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. 2012 , 47, 125-40	
899	Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. 2012 , 122, 148-57	18
898	Impact of antiplatelet therapy in heart disease. 2012 , 47, 5-19	4
897	Prasugrel. 2012 , 47, 39-63	3
896	Review of ticagrelor in the management of acute coronary syndromes. 2012 , 8, 1315-25	1

895	Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTEMI-ACS). 2012 , 30, e16-22	3
894	Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management. 2012 , 30, e41-50	5
893	Novel platelet ADP P2Y ₁₂ inhibitors in the treatment of acute coronary syndrome. 2012 , 30, e167-73	7
892	TRITON and beyond: new insights into the profile of prasugrel. 2012 , 30, e174-82	14
891	Novel treatments for cardiovascular disease prevention. 2012 , 30, 257-63	11
890	A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. 2012 , 30, e227-33	28
889	Glycoprotein IIb/IIIa inhibitors. 2012 , 30, e242-54	20
888	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. 2012 , 380, 1317-24	177
887	Improving long-term outcome after myocardial infarction. 2012 , 380, 1290-1	
886	Pharmacogenetic guidance for antiplatelet treatment – Authors' reply. 2012 , 380, 725-726	
885	Acute gastrointestinal bleeding after percutaneous coronary intervention. 2012 , 6, 211-21	3
884	Almanac 2012: interventional cardiology: the national society journals present selected research that has driven recent advances in clinical cardiology. 2012 , 98, 1701-9	11
883	What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. 2012 , 35, 669-72	2
882	Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. 2012 , 22, 1998-2006	100
881	Biomarkers in acute coronary artery disease. 2012 , 162, 489-98	7
880	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). 2012 , 223, 1-68	286
879	Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. 2012 , 17, 296-309	46
878	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. 2012 , 144, 762-70	9

877	Assessing Bleeding Risk in Acute Coronary Syndromes. 2012 , 65, 4-6	1
876	Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. 2012 , 65, 205-207	1
875	Platelet inhibition in acute coronary syndromes: A complex intervention that needs optimization. 2012 , 31, 275-277	1
874	Residual platelet activity in patients managed with clopidogrel: Clinical implications for the management of patients with acute coronary syndrome. 2012 , 31, 555-557	
873	Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. 2012 , 129, 616-22	19
872	Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey. 2012 , 64, 54-9	1
871	Desensitization to prasugrel: cardiology's increased need for allergy consultation. 2012 , 108, 124-5	11
870	Stenting in Acute STEMI Intervention. 2012 , 1, 507-520	1
869	¿Qu ^o aportan las gu ^{as} europeas de revascularizaci ^o n?. 2012 , 12, 14-20	
868	Gastroesophageal hymenoptera stings add to causes of idiopathic anaphylaxis. 2012 , 108, 125-6	5
867	[Residual platelet activity in patients managed with clopidogrel: clinical implications for the management of patients with acute coronary syndrome]. 2012 , 31, 555-7	1
866	Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. 2012 , 60, 2032-40	68
865	Quelles indications pour le prasugrel et le ticagrelor dans les syndromes coronariens aigus?. 2012 , 2012, 31-35	
864	Angina inestable/infarto de miocardio sin elevaci ^o n del segmento ST: las directrices m ^o s recientes. 2012 , 30, 8-15	
863	Women and the management of acute coronary syndrome. 2012 , 90, 1151-9	13
862	Un commento alla Lettera sulla definizione di farmaco innovativo. 2012 , 14, 71-73	
861	Antiplatelet therapy in acute coronary syndromes. 2012 , 13, 27-42	4
860	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). 2012 , 33, 1685-701	2797

859	Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. 2012 , 46, 39-44	8
858	Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. 2012 , 1, 222-31	53
857	[Medical management of coronary artery disease]. 2012 , 154 Spec No 3, 86-9; quiz 90	
856	[Tumor associated pain in GP's office]. 2012 , 154 Spec No 3, 92-6; quiz 97-8	
855	Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. 2012 , 12, 207-16	1
854	Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. 2012 , 12, 83-91	5
853	[Update coronary artery disease: important progresses in acute and chronic therapy]. 2012 , 154, 58-60	
852	[Myocardial revascularization]. 2012 , 53, 1063-75; quiz 1076-8	1
851	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). 2012 , 19, 585-667	233
850	Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. 2012 , 17, 164-72	148
849	Assessing bleeding risk in acute coronary syndromes. 2012 , 65, 4-6	11
848	Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet. 2012 , 65, 205-7	7
847	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. 2012 , 65, 173.e1-173.e55	15
846	Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. 2012 , 129, 623-8	29
845	Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. 2012 , 130, 65-9	37
844	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. 2012 , 130, 70-4	9
843	Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. 2012 , 92, 87-95	316
842	PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 2012 , 239-60	10

841	Ticagrelor in the treatment of coronary artery disease patients. 2012 , 9, 373-390	
840	Nucleic acid scavengers inhibit thrombosis without increasing bleeding. 2012 , 109, 12938-43	81
839	Acute coronary syndrome in patients with atrial fibrillation: what is the benefit/risk profile of triple antithrombotic therapy?. 2012 , 126, 1176-8	3
838	Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. 2012 , 126, 1645-62	25
837	Unstable angina and non-ST elevation myocardial infarction. 2012 , 185, 924-32	37
836	Ready when you are: easing into preemptive pharmacogenetics. 2012 , 92, 412-4	8
835	Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options. 2012 , 32, 139-44	4
834	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BASel Stent Kosten Effektivit�s Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. 2012 , 163, 136-41.e1	11
833	A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. 2012 , 163, 27-32	47
832	A case where the principle of "one question, one answer" may work better. 2012 , 163, 133-5	
831	Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. 2012 , 163, 95-103	
830	Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. 2012 , 163, 182-90.e4	83
829	Rationale and design of the TAXUS Libert�Post-Approval Study: examination of patients receiving the TAXUS Libert�stent with concomitant prasugrel therapy in routine interventional cardiology practice. 2012 , 163, 142-8.e6	4
828	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. 2012 , 163, 563-71	32
827	Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?. 2012 , 163, 531-4	3
826	Rationale and design of the Cangrelor versus standard therapy to aCHieve optimal Management of Platelet InhibitIOn PHOENIX trial. 2012 , 163, 768-776.e2	64
825	High on treatment platelet reactivity. 2012 , 21, 12-21	16
824	Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. 2012 , 155, 424-9	9

823	A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. 2012 , 160, 109-13	13
822	Very late stent thrombosis after drug eluting stent: management therapy guided by intravascular ultrasound imaging. 2012 , 154, 349-51	1
821	Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. 2012 , 158, 181-5	16
820	Newer Pharmaceutical Agents for STEMI Interventions. 2012 , 1, 429-440	
819	Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. 2012 , 10, 22	10
818	Nonadherence to treatment protocol in published randomised controlled trials: a review. 2012 , 13, 84	54
817	Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. 2012 , 11, CD005449	7
816	Research update for articles published in EJCI in 2010. 2012 , 42, 1149-1164	1
815	Update on pharmacology of antiplatelets, anticoagulants, and thrombolytics. 2012 , 79, S68-76	10
814	A new era in secondary prevention after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 85-7	59.2 30
813	A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. 2012 , 91, 829-37	19
812	Oral factor Xa inhibitors for the long-term management of ACS. 2012 , 9, 392-401	5
811	Clopidogrel in coronary artery disease: update 2012. 2012 , 47, 31-8	3
810	Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous coronary interventions. 2012 , 25, 278-88	4
809	Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. 2012 , 51, 429-42	58
808	Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. 2012 , 51, 305-18	41
807	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. 2012 , 72, 2087-116	85
806	Preventive aspects in peripheral artery disease. 2012 , 6, 53-70	6

805	New directions in antiplatelet therapy. 2012 , 5, 433-45	52
804	Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. 2012 , 17, 1447-85	54
803	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. 2012 , 10, 489-503	10
802	Acute Coronary Syndromes (ST Elevation and Non-ST Elevation). 2012 , 86-116	
801	Stent thrombosis in patients with chronic kidney disease. 2012 , 10, 617-26	
800	Stent thrombosis: an overview. 2012 , 10, 599-615	12
799	Quelle place pour les nouveaux anti-agrégants plaquettaires dans la stratégie thérapeutique ?. 2012 , 4, 195-199	
798	Les anti-agrégants plaquettaires dans les syndromes coronaires aigus : rapport bénéfice/risque. 2012 , 4, 217-222	
797	Anti-agrégants plaquettaires et syndromes coronaires aigus : état des lieux et limites actuelles. 2012 , 4, 232-235	
796	Gestion pharmaco-clinique des antiplaquettaires. 2012 , 4, 236-239	1
795	Ticagrelor versus clopidogrel : étude PLATO Le point de vue du méthodologiste. 2012 , 4, 240-246	
794	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. 2012 , 164, 327-33	8
793	Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatid in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. 2012 , 164, 817-24.e13	16
792	PAR-1 inhibitor antiplatelet agents: performance below par?. 2012 , 64, 594-7	
791	Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. 2012 , 59, 891-900	50
790	Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. 2012 , 59, 1681-7	16
789	Clinical application of cardiovascular pharmacogenetics. 2012 , 60, 9-20	53
788	A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. 2012 , 59, 2159-64	484

787	Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. 2012 , 59, 2338-43	91
786	Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. 2012 , 60, 369-77	37
785	Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 2012 , 60, 388-96	146
784	Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?. 2012 , 60, 378-80	
783	Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. 2012 , 60, 193-9	164
782	2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 , 60, 645-81	450
781	Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. 2012 , 60, 1623-30	66
780	Angiographic stent thrombosis at coronary bifurcations: short- and long-term prognosis. 2012 , 5, 57-63	15
779	Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. 2012 , 5, 293-300	38
778	Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of	140
777	Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. 2012 , 5, 958-65	64
776	Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. 2012 , 5, 1097-105	79
775	CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. 2012 , 5, 1280-7	81
774	Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. 2012 , 5, 1231-8	27
773	Antithrombotic strategies to reduce adverse clinical outcomes in patients with acute coronary syndrome. 2012 , 110, 1200-6	5
772	Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 2012 , 110, 1598-606	4
771	Cardiovascular disease in women. 2012 , 37, 450-526	44
770	Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. 2012 , 54, e32-e38	2

769	First issue of "new magazine" Cor et Vasa published by new publisher. 2012 , 54, e1-e2		
768	Novel methods in interventional cardiology and cardiac surgery. 2012 , 54, e135-e136		1
767	Resistance to antiplatelet treatment: The clinical relevance of platelet function assays. 2012 , 54, e305-e313		2
766	P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. 2012 , 130, e31-6		14
765	Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. 2012 , 6, 167-77		7
764	[Efficacy and tolerability of a clopidogrel desensitization protocol]. 2012 , 138, 684-5		1
763	Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. 2012 , 8, 889-900		3
762	Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. 2012 , 33, 1395-400		12
761	Use of cilostazol in percutaneous coronary interventions. 2012 , 46, 839-50		10
760	Antiplatelet agents in ischemic heart disease. 2012 , 495-518		1
759	Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. 2012 , 8, 223-35		14
758	Bedside monitoring to adjust antiplatelet therapy for coronary stenting. <i>New England Journal of Medicine</i> , 2012 , 367, 2100-9	59.2	637
757	Rivaroxaban in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 9-19	59.2	1357
756	Anticoagulant, Antiplatelet, and Thrombolytic Drugs. 2012 , 535-542		
755	New anti-platelet agents: the end of resistance?. 2012 , 130 Suppl 1, S53-5		6
754	The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. 2012 , 7, 299-304		3
753	Plättchenaggregationshemmer. 2012 , 6, 399-411		1
752	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2012 , 19, 403-88		196

751	[Platelet inhibition in acute coronary syndromes: a complex intervention that needs optimization]. 2012 , 31, 275-7	1
750	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). 2012 , 65, 937.e1-937.e66	7
749	Lessons Learned from STEMI Clinical Trials. 2012 , 1, 401-407	
748	The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. 2012 , 60, 2005-16	31
747	[Acute coronary syndrome -- 2012]. 2012 , 153, 2009-15	3
746	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. 2012 , 1, 223-230	3
745	Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 2012 , 5, 680-8	144
744	P2Y12 receptor: platelet thrombus formation and medical interventions. 2012 , 96, 572-87	11
743	Manual of Outpatient Cardiology. 2012 ,	
742	Acute coronary syndromes: from the emergency department to the cardiac care unit. 2012 , 30, 617-27	1
741	Kommentar zu den gemeinsamen "Guidelines on myocardial revascularization" der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS). 2012 , 26, 236-244	
740	Adverse drug events as a cause of hospitalization in older adults. 2012 , 35 Suppl 1, 29-45	98
739	Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 2012 , 5, 347-56	25
738	The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. 2012 , 30, 1067-84	27
737	Clopidogrel. 2012 , 12, 361-374	8
736	InforMatrix: ADP antagonists in acute coronary syndromes. 2012 , 13, 357-85	
735	Management of Myocardial Reperfusion Injury. 2012 ,	88
734	A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatid in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction. 2012 , 89, 87-95	12

733	Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. 2012 , 68, 1501-8	22
732	Combined blockade of ADP receptors and PI3-kinase p110 β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation. 2012 , 7, e38455	15
731	Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. 2012 , 42, 382-9	9
730	'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unproven. 2012 , 108, 1028-30	1
729	Towards personalized medicine based on platelet function testing for stent thrombosis patients. 2012 , 2012, 617098	9
728	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. 2012 , 108, 101-6	22
727	ST Elevation Myocardial Infarction in the elderly. 2012 , 9, 108-14	5
726	Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months. 2019 , 14, 68-70	3
725	Atopaxar. A novel player in antiplatelet therapy?. 2012 , 32, 228-33	2
724	Potent P2Y ₁₂ receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. 2013 , 33, 9-15	5
723	Platelet function testing to time surgery in patients on dual antiplatelet therapy?. 2014 , 34, 40-5	3
722	Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. 2019 , 26, 1-7	4
721	A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. 2015 , 17, e26904	4
720	Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. 2015 , 7, e28099	14
719	P2Y ₁₂ platelet receptors: importance in percutaneous coronary intervention. 2013 , 101, 277-82	3
718	. 2017 , 109, 1-76	119
717	Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events. 2019 , 74, e1222	2
716	Ticagrelor versus prasugrel in patients with acute myocardial infarction. 2021 , 344, 25-30	0

- 715 Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis. **2021**, 1 0
- 714 Antiplatelet Therapy and Periprocedural Risk Factor Analysis for Pipeline Embolization Device Treatment of Unruptured Internal Carotid Artery Aneurysms: A Retrospective, Multicenter Analysis. **2021**, 157, e102-e102
- 713 Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis. **2021**, 38, 1003-1016
- 712 [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?]. **2021**, 62, 1243-1252 0
- 711 Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention. **2021**, 8, 745549 0
- 710 Endogenous fibrinolysis inhibitors in acute coronary syndrome. **2021**, 10, 100058
- 709 Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. **2021**, 11, 20826 0
- 708 Gene polymorphisms of insulin secretion signaling pathway associated with clopidogrel resistance in Han Chinese population. **2021**, 35, e23970 2
- 707 Validation of the 4-Item PRECISE-DAPT Score: A SWEDEHEART Study. **2021**, 10, e020974 0
- 706 Complications related to veno-arterial extracorporeal membrane oxygenation in patients with acute myocardial infarction: VA-ECMO complications in AMI. **2021**, 0
- 705 De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials. **2021**, 1 2
- 704 Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives. **2021**, 0
- 703 Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China. **2021**,
- 702 The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2021. **2021**, 0
- 701 Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. **2021**, 398, 1305-1316 17
- 700 Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia. **2021**, 11, 0
- 699 Anti-platelet therapies. **2008**, 35-44
- 698 Antiplatelet agents for ischemic stroke: current status and future directions. **2008**, 30, 834-840

- 697 Anti-platelet treatment for acute coronary syndrome in Japan. **2008**, 19, 504-509
- 696 [Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. **2008**, 149, 483-91
- 695 Anti-platelet therapies. **2009**, 37-48
- 694 Intensity of antiplatelet therapy and percutaneous coronary intervention. **2009**, 1,
- 693 Prasugrel. **2009**, 1-4
- 692 Current status and limitation of thienopyridine antiplatelets. **2009**, 20, 329-335
- 691 4. Clinical Perspectives of New Antiplatelet Drugs. **2009**, 40, 273-278
- 690 Pre-procedural Patient Preparation. **2009**, 97-109
- 689 Pharmacological Support. **2009**, 93-109
- 688 Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. **2009**, 293-340
- 687 Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. **2009**, 20, 48-55
- 686 Antithrombotic therapy after acute myocardial infarction. **2009**, 51, 112-117
- 685 Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. **2009**, 471-484
- 684 Direct P2Y₁₂Antagonists. **2009**, 485-498
- 683 Overview of Antiplatelet Therapy. **2009**, 399-408
- 682 Markers of Platelet Function. **2009**, 409-428
- 681 The Role of Platelet Function Testing in the Development of Platelet Inhibitors. **2009**, 99-116
- 680 Platelet Glycoprotein IIb-IIIa Inhibitors. **2009**, 67-76

679 Platelet Glycoprotein IIb/IIIa Inhibitors. **2009**, 67-76

678 Thienopyridines in Stable Coronary Disease. **2010**, 131-141

677 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. **2010**, 219-233

676 Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction. **2010**, 145-163

675 Antithrombotic Therapy in Percutaneous Coronary Intervention. **2010**, 261-282

674 Transcatheter cardiac catheterization. **2009**, 106, 685-91

3

673 Aterotrombóza: antiagregációk. **2009**, 51, 19-21

1

672 Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. **2010**, 2010, 82-84

671 Farmacogenética de la terapéutica anticoagulante. **2010**, 113-136

670 Coronary Artery Disease. **2010**, 23-95

669 Acute Coronary Syndromes. 1-22

668 Early Discharge After Primary PCI. **2010**, 267-273

667 Oral Antiplatelet Therapy. **2010**, 73-82

666 Prasugrel. **2010**, 31,

665 Special Management of Diabetic Patients with STEMI. **2010**, 183-196

664 Primary Angioplasty. **2010**, 114-125

663 Cardiology. 185-193

662 Adjunctive Pharmacologic Therapies. **2010**, 54-64

661 Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. **2010**, 14, 31-38

1

660 Coronary Artery Stenting. **2011**, 243-261

659 Pharmacology in the Cardiac Catheterization Laboratory. 428-447

658 Percutaneous Coronary Intervention for Acute Myocardial Infarction. 356-369

657 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225

656 Clopidogrel and Salicylates. **2011**, 139-153

655 Oral antiplatelet therapy. **2011**, 311-319

654 Applying evidence-based medicine in the coronary care unit. **2011**, 12-18

653 Percutaneous coronary intervention. **2011**, 434-443

652 Management of ST-elevation myocardial infarction. **2011**, 474-484

651 Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. **2011**, 971-991

650 Acute coronary syndromes. **2011**, 467-474

649 Antiplatelet Therapy. **2011**, 69-85

648 Revascularization in Non-âST-Segment Elevation Acute Coronary SyndromeâFor Whom, When, and How?. **2011**, 299-312

647 Gestes rachidiens et anti-agrégation plaquettaire. **2011**, 267-271

646 Management of the postcoronary patient. **2011**, 650-659

645 Pharmacogenetics. **2011**, 65-72

644 Thrombolytics/Anticoagulants. **2011**, 1-67

643 Acute Coronary Syndromes. **2011**, 548-558

642 Antiplatelet Therapy. **2011**, 201-221

641 Bleeding in the Acute Coronary Syndromes. **2011**, 322-329

640 Antithrombotic therapy in secondary prevention. **2011**, 30, 224-233

639 Acute coronary syndromes. **2011**, 459-467

638 Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy. **2011**, 313-321

637 Invasive Cardiac Procedures. **2011**, 559-564

636 Oral Antiplatelet Agents in PCI. 101-109

635 Unstable Angina and Non-ST Elevation Myocardial Infarction. 43-52

634 Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines. **2011**, 2, e0056 1

633 Acute Coronary Syndromes. **2012**, 19-50

632 Antithrombotic Therapy for Non-ST-Elevation Acute Coronary Syndrome. 223-240

631 CardiologyâDepth Look: Advances in Antiplatelet Therapy.

630 Thrombolytic Intervention. **2012**, 142-158

629 Limitation of the evidenced based approach in the era of recently developed antithrombotic agents. **2012**, 23, 3-7

628 Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes. **2012**, 223-236

627 Impact of Concomitant Use of Clopidogrel and Proton Pump Inhibitor on Clinical Outcome in Coronary Stented Patients: A Retrospective Study. **2012**, 43, 393-398

626 Anästhesie bei Erkrankungen von Herz und Kreislauf. **2012**, 1182-1231 1

- 625 Clinical Analysis of the Pharmacological Interactions of Clopidogrel and Gender Differences: A Case-Control Study. **2012**, 03, 518-523
- 624 Anästhesie bei Patienten mit Störungen der Blutgerinnung. **2012**, 1302-1313
- 623 Design and Conduct of Clinical Trials. **2012**, 49-55
- 622 Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. **2012**, 1844-1867
- 621 P2Y12 and P2Y12-related genetic analysis. **2012**, 23, 450-456
- 620 Haemostasis and thrombosis. **2012**, 294-308
- 619 Cardiovascular Disease. **2012**, 478-549
- 618 Cardiac Catheter Laboratory. **2012**, 103-133
- 617 Clinical significance of monitoring tests for anti-platelet drugs. **2012**, 23, 352-357 1
- 616 Pharmacogenomics of Cardiovascular Drugs. 98-126
- 615 Interventional approaches to acute coronary syndromes. **2012**, 90-96
- 614 Final tips in interpreting evidence-based medicine. **2012**, 105, 173-80
- 613 Antithrombotic therapies. **2012**, 44-66
- 612 Gastroesophageal Reflux Disease. 175-193
- 611 Treatment algorithm in patients with stable angina. **2012**, 312-330
- 610 Interventional perspectives on the management of advanced stable coronary artery disease. **2012**, 385-393
- 609 Antithrombotic pharmacotherapy in patients with established coronary artery disease. **2012**, 287-301
- 608 Antithrombotic Therapy in Non-âST-Segment Elevation Acute Coronary Syndromes. 213-235

- 607 Platelet ADP P2Y12 Inhibitors: Thienopyridines. 26-46
- 606 Novel antithrombotic agents & future directions. **2012**, 128-141
- 605 Platelet ADP P2Y12 Inhibitors: Nonthienopyridines. 47-61
- 604 Acute coronary syndromes. **2012**, 34-57
- 603 Antithrombotic management in the acute coronary syndrome setting. **2012**, 82-98
- 602 Genetics of the Response to Antithrombotic Drugs and the Need for Monitoring. 357-377
- 601 [Novel agents for antithrombotic therapy in cardiology]. **2012**, 153, 2016-20
- 600 Thienopyridyl and Direct-Acting P2Y12 Receptor Antagonist Antiplatelet Drugs. 141-164
- 599 New Oral Antiplatelet Agents. **2013**, 85, 10 2
- 598 Global Clinical Trial. **2013**, 24, 282-285
- 597 Almanac 2012: Cardiovascular risk scores: The national society journals present selected research that has driven recent advances in clinical cardiology. **2013**, 32, 317-326
- 596 Diabetes and the Cardiovascular System. **2013**, 701-714
- 595 Regulatory science for antiplatelet therapies. **2013**, 24, 269-281
- 594 Antithrombotic and Antiplatelet Therapy for Percutaneous Coronary Interventions. **2013**, 130-146
- 593 Preventive Cardiology. **2013**, 767-780
- 592 Akute koronare Syndrome. **2013**, 113-121
- 591 Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. **2013**, 469-506
- 590 Kardiologische Therapie bei Hochbetagten. **2013**, 433-446

589 Agents antiplaquettaires et athfthrombose. **2013**, 197, 375-388

588 Almanac 2012: Interventional cardiology. **2013**, 83, 138-48

587 Management of the Urological Patient Taking Anticoagulant or Antiplatelet Medication. **2014**, 271-289

586 Lâĩnfarctus du myocarde, une pathologie ^ traiter sans d'âi. **2013**, 58, 17-19

1

585 Secondary Prevention in ACS: The Role of Novel Oral Anticoagulants. **2014**, 123-138

584 American Versus European Guidelines: Critical Appraisal. **2014**, 139-184

583 Triple Therapy: Risky but Sometimes Necessary. **2014**, 185-212

582 Antiplatelet Therapy. New Potent P2Y12 Inhibitors. **2014**, 31-57

581 Patient Selection for Coronary Intervention. **2014**, 41-51

580 PCI Considerations in Women: Gender-Specific Outcomes and Challenges. **2014**, 227-241

579 Adjunctive Pharmacology for Coronary Intervention. **2014**, 143-156

578 Percutaneous Coronary Interventions in the Elderly. **2014**, 243-252

577 Cardiovascular Problems in the Elderly. **2014**, 267-281

576 Acute Coronary Syndromes. **2014**, 15-36

1

575 Interventional Management of Acute Myocardial Infarction. **2014**, 207-220

574 Invasive Therapy for Women Presenting with Acute Coronary Syndromes. **2014**, 113-138

573 Antithrombotic Issues in Women. **2014**, 321-357

572 Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes. **2014**, 1-43

- 571 Antithrombotika und Antihorrhagika. **2014**, 469-490
- 570 A Case of Ticagrelor Rescue Therapy in a Patient with Subacute Stent Thrombosis. **2014**, 87, 598
- 569 Prevention of Cardiovascular Disease in Older Adults. **2014**, 1-28
- 568 Optimizing Intensity and Duration of Oral Antithrombotic Therapy after Primary Percutaneous Coronary Intervention. **2014**, 569-581
- 567 Progress of antiplatelet therapy. **2014**, 36, 210-215
- 566 Antiplatelet Drugs in the Management of Cardiovascular Indications. **2014**, 1-24
- 565 Anti-Platelet Therapy. **2014**, 73, 76-77
- 564 Medical Management of Coronary Artery Disease. **2014**, 1-17
- 563 Cardiac disease and anaesthesia. **2014**, 235-260
- 562 Thrombosis in Diabetes and Its Clinical Management. 185-214
- 561 THE ROLE OF GENETIC TESTING FOR OPTIMAL ANTIPLATELET THERAPY SELECTION IN THE TREATMENT OF CORONARY ARTERY DISEASE PATIENTS. **2014**, 13, 71-75 1
- 560 Perioperative Coagulation in Cardiovascular Surgery. **2015**, 243-266
- 559 CONTEMPORARY APPROACHES TO ANTIPLATELET THERAPY IN CORONARY HEART DISEASE TREATMENT. **2014**, 13, 69-74
- 558 Antiplatelet Therapy in Patients with Coronary Stent Undergoing Orthopedic Surgery: Is It Still No Man's Land?. **2015**, 41-49
- 557 Genomic Applications in Pharmacogenomics. **2015**, 553-562
- 556 Epicardial Coronary Heart Disease in CKD: Diagnosis and Management. **2015**, 3-12
- 555 The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG).
- 554 Medical Management of Coronary Artery Disease. **2015**, 2369-2382

553 Advances in Antiplatelets. **2015**, 1-5

552 Akutes Koronarsyndrom (außer STEMI). **2015**, 1-13

551 Drug-Eluting Stents and Coronary Artery Disease. **2015**, 495-524

550 Are There Any Racial and Ethnic Differences in Response to Medicines in Japanese Patients?. **2015**, 22, 550-2

549 Ischemic Heart Disease. **2015**, 1-9

548 Coronary Stent Thrombosis in 2015: A Comprehensive and Updated Review. **2015**, 2, 131-149

547 ST Elevation Related to the Site of Coronary Occlusion. **2015**, 3-15

546 Gestion pharmaceutique des patients traités par antithrombotiques en chirurgie orale. Argumentaire. **2015**, 21, S15-S81

1

545 Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes. **2015**, 2071-2107

544 Carotid artery stenting under dual antiplatelet therapy using prasugrel: a novel antiplatelet agent. **2015**, 9, 278-283

1

543 Prognosis of Patients with Acute Coronary Syndromes and Bleeding - The Importance of Routine Use of a Bleeding Risk Score. **2015**, 05, 327-334

542 DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. **2015**, 255-269

541 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. **2015**, 187-235

540 Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy. **2015**, 10, 16-21

539 Results of clinical studies PLATO and place of ticagrelor in the treatment of acute coronary syndrome. **2015**, 6, 53-59

1

538 Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. **2015**, 30, 319-24

537 Assessment of coronary flow reserve by Doppler flow wire in patients with acute coronary syndrome undergoing percutaneous coronary intervention: differences between the Loading dose of Ticagrelor versus prasugrel (DILATE): study protocol for a randomized controlled trial. **2016**, 1, 154

536 Remaining issues in antithrombotic therapy. **2016**, 22, 45-50

- 535 Advances in Antiplatelets. **2016**, 827-831
- 534 Role of Antiplatelet Therapy in Neurosurgery: Efficacy and Safety Profiles. **2016**, 65-89
- 533 Anästhesie bei Patienten mit Störungen der Blutgerinnung. **2016**, 1-18
- 532 Obesity and Coronary Heart Disease. **2016**, 107-116
- 531 Management of Angina. **2016**, 111-163
- 530 Efficacy and safety of short-term (â€ 3 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials. **2017**, 17, 168-175 1
- 529 Overview of antiplatelet and anticoagulant therapy after acute myocardial infarction. **2016**, 15, 45-50
- 528 Ticagrelor in patients with acute coronary syndrome without ST elevation and a conservative treatment strategy. **2016**, 7, 51-55
- 527 How should I treat a massive left main coronary artery thrombosis in a 49-year-old woman in the context of cardiogenic shock?. **2016**, 11, e1687-90
- 526 Peri- and Post-procedural Antithrombotic Therapy in Women. **2017**, 73-100 0
- 525 Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria. **2016**, 18, 184-190
- 524 Review of Antiplatelet Therapy for the Management of Acute Coronary Syndromes. **2016**, 02, 34-35
- 523 Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. **2017**, 19-38
- 522 Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. **2017**, 95-120
- 521 Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. **2017**, 39-58
- 520 Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. **2017**, 121-140
- 519 Factores determinantes del riesgo isqu mico del paciente tras un infarto agudo de miocardio. **2017**, 17, 9-15
- 518 Indicaci n del tratamiento con doble antiagregaci n m s all  del a . A qui n y por qu ? **2017**, 17, 24-29

517 Treatment of Acute Coronary Syndromes in Elderly Patients. **2017**, 165-177

516 Novedades en la evaluación del riesgo hemorrágico del paciente con cardiopatía isquémica. **2017**, 17, 16-23

515 Acute Coronary Syndrome. **2017**, 194-225

514 Antiplatelet and anticoagulant therapy in patients with coronary artery disease. **2017**, 23, 117-119

513 Anästhesie bei Patienten mit Shuntvitien. **2017**, 1-8

512 Myocardial Infarction. **2017**, 13-18

511 Revascularization Strategies in CKD: Antiplatelet Therapy, Stent Type, Timing, and Complications of PCI. **2017**, 329-335

510 Prasugrel ?. **2017**,

509 Efectos cardioprotectores del ticagrelor. **2017**, 17, 3-8

508 Antiplatelet Therapy in Patients with Coronary Artery Disease. **2017**, 1361-1371

507 Stroke Pharmacogenetics. **2017**, 327-410

506 Platelet Inhibition as a Therapeutic Approach in Intravascular Intervention. **2017**, 99-109

505 Anästhesie bei Patienten mit Herzinsuffizienz. **2017**, 1-14

504 Management of Acute Coronary Syndrome. **2017**, 111-120

503 Personalized Therapeutics: First Take Home Messages. **2017**, 11-23

502 Incidence of Cardiovascular Events: A comparative study of Dual Anti-Platelet Therapies in Patients with Percutaneous Coronary Intervention. **2017**, 34, 313-321

501 Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials. **2017**, 5, 1-406

3

500 Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review. **2017**, 13, 325-333

- 499 PCR Peripheral @ GISE: a unique educational link between peripheral endovascular solutions and interventional cardiologists. **2017**, 13, e1013-e1017
- 498 Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE. **2017**, 13, 1133-1135 1
- 497 Anästhesie bei Patienten mit koronarer Herzkrankheit (KHK). **2018**, 1-17
- 496 Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. **2018**, 73-89
- 495 OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management. **2018**,
- 494 Non-ST-Segment Elevation Acute Coronary Syndromes (NSTEMI/ACS). **2018**, 91-106
- 493 Dual antiplatelet therapy in coronary artery disease. **2018**, 37, 45-50
- 492 Bleeding Associated with Angiography and Percutaneous Coronary Intervention. **2018**, 503-522
- 491 Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Is Less More?. **2018**, 12, 91
- 490 Percutaneous Coronary Intervention: Adjunctive Pharmacology. **2018**, 161-180
- 489 Possibility of novel monitoring system for thrombus formation in patients with coronary artery disease. **2018**, 24, 156-160
- 488 Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. **2018**, 291-303
- 487 Utilization of PCI After Fibrinolysis. **2018**, 53-67
- 486 Gastroenterological Perspectives on Acute Cardiac Care – The Management of Patients with Implanted Coronary Stents Following an Acute Coronary Syndrome. **2018**, 4, 8-16
- 485 Update of antithrombotic treatment. **2018**, 17, 123-125
- 484 On-treatment platelet reactivity in the era of new ADP receptor blockers: data from a real-world clinical practice. **2018**, 18, 34-39 0
- 483 Nachbehandlung: Patientenversorgung nach interventionellen Eingriffen.
- 482 Anticoagulation after mechanical aortic valve implantation: is it time to act after PROACT?. **2018**, 6, S16 0

481 Antiplatelet Therapy in Cardiovascular Disease. **2019**, 195-207

480 Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma. **2018**, 10, e3720

1

479 EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?. **2018**, 76-86

478 Intervenci3 coronaria en pacientes con fibrilaci3 auricular. **2019**, 18, 15-20

477 An3sthesie bei Patienten mit St3rungen der Blutgerinnung. **2019**, 1753-1770

476 Diabetes and Cardiovascular Disease. **2019**, 709-730

475 Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity. **2019**, 17, 127-132

1

474 Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients. **2019**, 17, 191-203

1

473 An3sthesie bei Patienten mit koronarer Herzkrankheit (KHK). **2019**, 1589-1605

472 Stable Ischemic Heart Disease in the Older Adult. **2019**, 3, 291-296

471 Patient with diabetes after acute coronary event. How to improve forecast?. **2019**, 1, 6-11

470 Anticoagulation Options. **2019**, 474-498

469 Preliminary Experience of Preoperative Modification of Platelet Aggregation. **2019**, 13, 250-256

468 Antiplatelet Therapy Considerations in Women. **2019**, 3, 363-373

467 Pharmacological prophylaxis of bleeding in urological procedures. **2019**, 20, 13-18

466 [Therapeutic Strategies in Patients with Stable Coronary Artery Disease: The Role of Coronary Revascularization]. **2019**, 108, 401-409

1

465 Cardiovascular Disease. **2019**, 101-151

464 Synthesis and Characterization of Molecularly Imprinted Polymer for Prasugrel Drug Base on 2-Hydroxyethyl Methacrylate Monomer in Biological and Pharmaceutical Samples. **2019**, 10, 69-74

- 463 Infarto del miocardio: diagnosi, gestione e complicanze. **2019**, 21, 1-14
- 462 Infarto de miocardio: diagnóstico, tratamiento y complicaciones. **2019**, 23, 1-14
- 461 Acute coronary syndrome in elderly: aspects of patient management. **2019**, 13, 19-26 3
- 460 Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients. **2019**, 64-70
- 459 Consensus Report on Patient Blood Management in Cardiac Surgery by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Cardiology (TSC), and Society of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care (SCTAIC). **2019**, 27, 429-450 2
- 458 Ischemic Heart Disease. **2020**, 59-64
- 457 Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review. **2019**,
- 456 Hemostasis in Cardiac Surgery: How We Do it with Limited Resources.
- 455 (In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction). **2019**, 61, 606-610
- 454 Ischemic Heart Disease. **2020**, 1-10
- 453 Antithrombotika und Antihämorrhagika. **2020**, 395-420
- 452 Management of Acute Coronary Syndrome. **2020**, 101-109
- 451 Acute Clinical and Procedural Outcome of Rajaie Cardiovascular Medical and Research Center Acute Coronary Syndrome Registry. **2020**, 9, 83
- 450 Emerging clinical setting of direct oral anticoagulants: atherothrombotic events prevention. **2020**, 21, 1-5
- 449 Strategia di gestione delle sindromi coronariche acute. **2020**, 24, 1-13
- 448 No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy. **2020**, 9, 2
- 447 Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. **2021**, 110, 162-171 0
- 446 The role of clopidogrel in the current treatment of acute coronary syndrome. **2020**, 72-81

- 445 Coronary stent thrombosis: the problem still persists. **2020**, 19, 117-121
- 444 What Is the Optimal Dual Antiplatelet Therapy Strategy After Percutaneous Coronary Intervention in the Era of New-Generation Drug-Eluting Stent?. **2020**, 84, 1459-1460
- 443 Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. **2020**, 84, 1582-1586 ○
- 442 Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention. **2020**, 25, 3809
- 441 Antiplatelet therapy after PCI in patients with high risk of bleeding. **2020**, 67, 135-143 ○
- 440 Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms. **2021**, ○
- 439 Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. **2020**, 26, 5988-5997 1
- 438 Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?. **2020**, 16, 1017-1023
- 437 Regarding the choice of P2Y₁₂ platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use. **2020**, 66-74
- 436 Meta-analysis of Duration of Continuous Dual Antiplatelet Therapy and Late Stent Thrombosis After Second-Generation Drug Stent Implantation. **2021**, 38, 1068-1077
- 435 Antiplatelet Therapy. **2021**, 249-288
- 434 Benefits of clopidogrel in clinical practice: current data. **2020**, 13, 322
- 433 Antiplatelet Agent Choice and Platelet Function Testing in CKD. **2020**, 103-118
- 432 Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock. **2020**, 16, 418-421
- 431 Acute Coronary Syndrome and Myocardial Infarction. **2020**, 131-140
- 430 Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?. **2020**, 13, 146-149
- 429 The Usefulness of Prasugrel as Rescue Medication in Neuroendovascular Therapy. **2020**, 14, 90-95 1
- 428 Unstable Angina/Non-ST Elevation Myocardial Infarction. **2020**, 99-110

- 427 Acute ST Elevation Myocardial Infarction. **2020**, 111-123
- 426 Dapt Review. **2020**, 5, 060-066 0
- 425 Impact of Pancreatic β Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention. **2021**, 1 1
- 424 Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. **2021**, 5
- 423 Terapia antiplaquetaria en c ncer. **2021**, 6, 63-73
- 422 P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or Ticagrelor. **2021**, 108029 0
- 421 Incidence and predictors of serious bleeding during long-term follow-up after acute coronary syndrome in a population-based cohort study. **2021**, 11, 21967 0
- 420 Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-analysis. **2021**,
- 419 Acute Coronary Syndrome. 136-167
- 418 Anticoagulation Options. 253-277
- 417 Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. **2015**,
- 416 Role of P2Y12 Receptor in Thrombosis. **2015**,
- 415 CYP2C19*2, CYP2C19*17 and ITGB3 (PIA1/A2) polymorphisms and resulting therapeutic alterations of clopidogrel and aspirin: A clinical screening among CVD patients who undergo PCI.
- 414 Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention. **2020**, 25, 4063
- 413 Administraci n upstream de inhibidores de la glucoprote na IIb/IIIa en el s ndrome coronario agudo sin elevaci n del segmento ST: la estrategia TACTICS. **2011**, 11, 27-32
- 412 Acute Coronary Syndrome. **2021**, 59-80
- 411 Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?. **2020**, 68, 436-450 1
- 410 Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction. **2020**, 12, 513-525

409	Percutaneous Coronary Intervention in Diabetic Patients.	
408	Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. 2020 , 39, 493-501	
407	Actualităţi en mdecine dăurgence. 2020 , 10, 413-420	
406	Aspirin and clopidogrel response variability: review of the published literature. 2008 , 35, 313-20	24
405	Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. 2009 , 84, 149-60	4
404	Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. 2009 , 10, 163-75	3
403	Platelet function analysis: at the edge of meaning. 2009 , 101, 217-9	1
402	Antiplatelet Resistance-Does it Exist and How to Measure it?. 2009 , 3, 77-91	4
401	Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). 2010 , 37, 262-75	9
400	Interventional cardiology: the repertoire continues to expand. 2010 , 37, 309-11	1
399	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. 2011 , 1, 255-63	1
398	Myocardial infarction in the elderly. 2011 , 2, 116-37	20
397	Past, present, and future of anti-platelet therapy. 2008 , 1, 57-60	1
396	Restoration of microcirculatory patency after myocardial infarction: results of current coronary interventional strategies and techniques. 2012 , 39, 342-50	5
395	Major themes for 2009 in cardiothoracic and vascular anesthesia. 2010 , 2, 81-91	3
394	Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions. 2013 , 3, 27-38	1
393	Development and course of heart failure after a myocardial infarction in younger and older people. 2014 , 11, 1-12	15
392	Management of atrial fibrillation in patients undergoing percutaneous coronary intervention. 2014 , 9, 33-7	1

- 391 Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. **2015**, 74, 16-20 6
- 390 Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. **2015**, 11, 14-23
- 389 Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. **2015**, 8, 800-8 2
- 388 In-hospital clinical outcomes of elderly patients (≥80 years) undergoing primary percutaneous coronary intervention. **2015**, 8, 11244-51 1
- 387 Platelet Function Testing-Guided Antiplatelet Therapy. **2013**, 24, 90-6 7
- 386 Dual antiplatelet therapy for secondary stroke prevention: Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke. **2016**, 62, 640-5 3
- 385 Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. **2015**, 8, 1318 5
- 384 Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4939 patients in China. **2017**, 14, 93-99 5
- 383 Triple antithrombotic therapy for atrial fibrillation and coronary stents. **2017**, 63, 375-381 3
- 382 Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome. **2017**, 14, 442-456 6
- 381 Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). **2017**, 29, 340-351 2
- 380 Comparative Review of Oral P2Y Inhibitors. **2018**, 43, 352-357 9
- 379 New anti-coagulant therapies set to revitalise clinical haematology practice. **2010**, 21, 323-6, 337
- 378 Update in the management of coronary artery disease. **2012**, 109, 137-41 1
- 377 Contemporary Prescription Patterns of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndrome. **2018**, 43, 667-674 1
- 376 Impact of Cytochrome P450 2C19 Reduced-Function Polymorphism on Lesions and Clinical Outcome in Japanese Patients After Drug-eluting Stent Implantation. **2018**, 64, E56-E63
- 375 Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. **2019**, 16, 103-113 6
- 374 PURL: Should you switch the DAPT agent one month after ACS?. **2019**, 68, 162;164

373	Non-ST elevation acute coronary syndrome in the elderly. 2020 , 17, 9-15	2
372	Role of MKP-5-p38/MAPK pathway in Clopidogrel-induced gastric mucosal epithelial cells apoptosis and tight junction dysfunction. 2020 , 12, 1741-1753	3
371	2020 Focused Update of the 2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction. 2020 , 36, 285-307	6
370	P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?. 2021 , 37, 1-8	2
369	Evaluation of safety of switching between oral P2Y12 inhibitors: a descriptive study. 2021 , 11, 108-114	
368	Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. 2021 , 18, 210-218	0
367	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.. 2021 ,	8
366	Coronary Stents: From Revolution, to Evolution, to Pursuit of Perfection. 2021 , 14, 2474-2476	1
365	Choosing the right potent P2Y12-receptor inhibitor in East Asians with acute myocardial infarction and percutaneous coronary intervention - Editorial on Ticagrelor versus Prasugrel in patients with acute myocardial infarction. 2022 , 347, 17-18	
364	Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk. 2021 , 22,	0
363	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. 2021 , 14, 2447-2457	1
362	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. 2021 ,	0
361	Acute myocardial infarction and cardiogenic shock Interventional approach to management in the cardiac catheterization laboratories. 2021 ,	1
360	Acute coronay syndrome in a patient with severe hemophilia A: Dificult decisions.. 2021 , 40, 985.e1-985.e5	
359	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). 2021 , 6-59	1
358	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. 2021 , ATVBAHA121317113	2
357	Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention - analysis from the Acute Coronary Syndrome Israeli Survey (ACSIS). 2021 ,	
356	Síndrome coronária aguda em doente com hemofilia A grave: decisões difíceis. 2021 , 40, 985.e1-985.e1	

- 355 Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials. **2021**, 21, 574
- 354 MicroRNAs as Novel Biomarkers for P2Y12 - Inhibitors Resistance Prediction. **2021**, 14, 1575-1582 1
- 353 Patienten nach Stentimplantation: Worauf ist zu achten?.
- 352 Diagnose stellen –muss es immer gleich der Herzkatheter sein?. **2021**, 83-97
- 351 Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes.. **2021**, 17, 340-343 0
- 350 Antithrombotika und Antihorrhagika. **2021**, 299-326 0
- 349 Long-term outcomes in inferior ST-segment elevation myocardial infarction patients with right ventricular myocardial infarction.. **2022**, 1
- 348 Periprocedural Myocardial Injury in High-Risk Patients with Non-ST-Elevation Myocardial Infarction Pre-Treated with Ticagrelor for Less or More than 6 Hours Before PCI.. **2021**,
- 347 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. **2021**, 42
- 346 Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines.. **2022**, 39, 100-132 5
- 345 Akutes Koronarsyndrom (außer STEMI). **2015**, 1-11
- 344 Akutes Koronarsyndrom: Wie geht es nach der Akutphase weiter?.
- 343 Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro. **2021**, 106, 2874-2884 1
- 342 Antithrombotic Management of Atrial Fibrillation Patients Presenting with Coronary Artery Disease: A Consensus Document of the Chinese Society of Cardiology. **2021**, 1, 15-28
- 341 Antithrombotic therapy in acute coronary syndromes setting: new clinical guidelines, controversial issues and the role of prehospital stage. **2022**, 22, 4-11
- 340 Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.. **2022**, 9, 805525 2
- 339 Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.. **2022**, 1
- 338 Antiplatelet Therapy in Acute Coronary Syndrome. **2022**, 10, 769-777

- 337 Trade-off of major bleeding versus myocardial infarction on mortality after percutaneous coronary intervention.. **2022**, 9,
- 336 Factors predicting the occurrence of net adverse clinical and cerebral events in patients with acute coronary syndrome treated with clopidogrel or ticagrelor in combination with aspirin: a real-world study.. **2022**, 10, 98
- 335 The effects of dual anti-platelet therapy on titanium implant osseointegration: an experimental study. **2022**, 5, 144-149
- 334 Ischemic Heart Disease. **2022**, 1055-1063
- 333 Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction From National Cardiovascular Data Registry Chest Pain-MI Registry.. **2022**, 15, e008112 0
- 332 CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.. **2022**, 37, 1 4
- 331 Dry Needling and Antithrombotic Drugs.. **2022**, 2022, 1363477
- 330 Non-ST-Segment Elevation Acute Coronary Syndrome. **2022**, 1-37
- 329 Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multi-center study.. **2022**, 0
- 328 Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!. **2022**,
- 327 Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial.. **2021**, 1
- 326 Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme. **2022**, 16, 61-68
- 325 The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction.. **2022**, 0
- 324 Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial.. **2022**, 1 1
- 323 Systemic Immune-Inflammation Index: A Novel Predictor of Coronary Thrombus Burden in Patients with Non-ST Acute Coronary Syndrome.. **2022**, 58, 1
- 322 Antiplatelet therapy in cardiovascular disease: current status and future directions.. **2022**, 3
- 321 Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. **2022**, 15, 282-282 0
- 320 Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial.. **2022**, 0

319	Effect of genotype guided oral P2Y12 inhibitor selection after percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.. 2022,	1
318	Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI.. 2021,	2
317	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.. 2022,	2
316	Antiplatelet Therapy in Older Patients Post-Myocardial Infarction.. 2022, 37, 17-23	
315	Infarto de miocardio con elevaci3n del segmento ST revascularizado. Tendencias temporales de los tratamientos contempor3neos y su impacto en los resultados. 2022,	0
314	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.. 2022,	14
313	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2021, CIR0000000000001038	23
312	Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy.. 2022,	
311	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: prognostic role and use of new P2Y receptor inhibitors.. 2022, 109215	
310	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. 2021, 36, 108101	2
309	Is There a Role for Triple Therapy After ACS?. 2022, 24, 191	
308	Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?. 2022, 14, 100309	
307	Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.. 2021, 246, 44-44	0
306	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.. 2022, e023454	0
305	Short- and Long-Term Outcomes in Patients With Right Ventricular Infarction According to Modalities of Reperfusion Strategies in China: Data From China Acute Myocardial Infarction Registry.. 2022, 9, 741110	0
304	Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review.. 2022, 22, 40	1
303	Contemporary Management of Stable Coronary Artery Disease.. 2022, 1	0
302	Predictors of in-hospital de-escalation of P2Y12 inhibitors to clopidogrel in patients with acute myocardial infarction treated with percutaneous coronary intervention.. 2022,	0

301	Índice de masa corporal y eficacia y seguridad del ticagrelor frente al prasugrel en pacientes con síndrome coronario agudo. 2022,	
300	Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials.. 2022, 74, 103330	
299	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.. 2021,	1
298	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. 2021, 22,	5
297	Importance of the Results of VOYAGER PAD Trial for Clinical Practice. 2021, 712-720	
296	Dual Pathway of Inhibition and Vascular Protection in Patients with Atherosclerotic Disease. 2021, 280-300	
295	Treatment of Chronic Cough: P2X3 Receptor Antagonists and Beyond.	
294	Diagnosis and Treatment of Acute Coronary Syndromes: A Review.. 2022, 327, 662-675	10
293	Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. 2022, 2, 1-18	0
292	Prevalence of High Bleeding Risk among Hospitalized Suspected NSTEMI Patients.. 2022, 11,	
291	Antiplatelet Agents in Acute ST Elevation Myocardial Infarction.. 2022,	
290	Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis.. 2022,	0
289	A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.. 2022, 194, E205-E215	0
288	Comparative evaluation of standard maintenance-dose clopidogrel versus low-dose prasugrel in patients with stable coronary artery disease after percutaneous coronary intervention.. 2022,	0
287	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial.. 2022,	1
286	Update of the Brazilian Society of Cardiology's Perioperative Cardiovascular Assessment Guideline: Focus on Managing Patients with Percutaneous Coronary Intervention - 2022.. 2022, 118, 536-547	
285	Percutaneous Coronary Intervention in Patients With Gynecological Cancer: Machine Learning-Augmented Propensity Score Mortality and Cost Analysis for 383,760 Patients.. 2021, 8, 793877	0
284	Antiplatelet agents for chronic kidney disease.. 2022, 2, CD008834	1

283 Ischaemic heart disease. **2022**, 388-399

282 Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor.. **2022**, 11, 1

281 Effectiveness and Safety of P2Y12 Inhibitors Pretreatment in Primary Percutaneous Coronary Intervention with Long Transfer Times.. **2021**, 0

280 Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review.. **2022**, 0

279 The Evolution of Antiplatelet Therapy Following Percutaneous Coronary Interventions: a 40-Year Journey.. **2022**, 0

278 Dual Antiplatelet Therapy with 3 Generation P2Y Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response.. **2022**, 1 3

277 Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia.. **2022**, 0

276 Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.. **2022**, 1 1

275 Stent farmacoadtivo y rgimen contemporneo de doble antiagregaci3n plaquetaria en el IAMCEST revascularizado. ¿Los tiempos est3n cambiando?. **2022**,

274 P2Y-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction.. **2022**, 117, 16 1

273 The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention.. **2022**, 0

272 Purinergic signaling in myocardial ischemia-reperfusion injury.. **2022**, 1 1

271 Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry.. **2022**, 9, 859962 0

270 Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.. **2022**, 0

269 Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. **2022**, CIRCINTERVENTIONS121011069

268 Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: A pharmacodynamic study of dual pathway inhibition versus dual antiplatelet therapy.. **2022**, 1

267 JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

266 Clinical Characteristics and Long-Term Outcomes of Patients With Differing Haemoglobin Levels Undergoing Semi-Urgent and Elective Percutaneous Coronary Intervention in an Asian Population.. **2022**, 9, 687555

265	P2Y12 Inhibitor versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Trials.	0
264	Extended, standard or De-escalation antiplatelet therapy for patients with CAD undergoing PCI? A trial-sequential, bivariate, influential and network meta-analysis.. 2022 ,	0
263	Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art.. 2022 , 9, 850028	1
262	Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2.. 2022 , e024749	0
261	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. 2022 , CJ-20-1212	6
260	Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives.. 2022 , 37, 255	1
259	Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome.. 2022 , 15, 2397-2414	1
258	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.. 2022 , 24, 277-293	0
257	Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.. 2022 ,	12
256	Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.. 2022 ,	0
255	A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry.. 2022 , 11,	0
254	Acute coronary syndromes.. 2022 , 399, 1347-1358	7
253	Antiplatelet therapy after percutaneous coronary intervention.. 2022 , 17, e1371-e1396	5
252	Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.. 2022 , 79, 407-419	0
251	Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry.. 2022 , 22, 142	0
250	Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery.. 2022 , 11, e024040	2
249	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization.. 2022 , 11,	
248	Treatment of chronic cough: P2X3 receptor antagonists and beyond.. 2022 , 108166	1

- 247 Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis. **2021**, 100, e27398
- 246 Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.. **2021**, 39, 754 ○
- 245 Real-world management and outcomes of 7 million patients with acute coronary syndrome according to clinical research trial enrollment status: A propensity matched analysis.. **2021**, ○
- 244 Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction.. **2021**, 14, e008969 1
- 243 Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease.. **2021**, 8, 773214 1
- 242 Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.. **2021**,
- 241 Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention.. **2021**, 8, 788137
- 240 Revascularized ST-segment elevation myocardial infarction. Temporal trends in contemporary therapies and impact on outcomes. **2021**,
- 239 Variation in in-hospital mortality and its association with percutaneous coronary intervention-related bleeding complications: A report from nationwide registry in Japan.. **2021**, 16, e0261371 ○
- 238 Antiplatelet effect, safety, and pharmacokinetics of ticagrelor in patients with coronary artery disease undergoing percutaneous coronary intervention.. **2022**, ○
- 237 Safety and efficacy of selective, clopidogrel-based strategies in acute coronary syndrome: a study-level meta-analysis.. **2022**, ○
- 236 Ischemic-hemorrhagic balance in diabetic and non-diabetic patients after acute coronary syndrome. **2022**, ○
- 235 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1
- 234 Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation.. **2022**, ○
- 233 Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS.. **2022**, 1
- 232 Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.. **2022**, 106762 1
- 231 Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis.. **2022**, 5, e227624 ○
- 230 Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.. **2022**, e024754 ○

229	Comparative efficacy and safety of oral P2Y inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis.. 2022 , 9,	
228	Cost-Utility of Prasugrel in Postangioplasty Diabetic Patients.. 2022 , 30, 134-139	
227	Data_Sheet_1.docx. 2018 ,	
226	Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.. 2022 ,	0
225	Preliminary therapeutic outcomes of using direct oral anticoagulants to treat venous thromboembolism in gynecological cancer patients.. 2019 , 5, 67-71	
224	Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring.. 2022 , 11,	1
223	Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium.. 2022 , 63, 413-421	0
222	Impact of pre-existing vascular disease on clinical outcomes in patients with non-ST-segment myocardial infarction: a nationwide cohort study.. 2022 ,	
221	Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. 2022 , 1, 105-110	
220	Early vs. Delayed Initiation of Treatment With P2Y Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.. 2022 , 9, 862452	1
219	De-escalation strategies of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. 2022 , 4, 63-69	
218	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines.. 2022 , 13, 878416	0
217	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. 2022 , 21, 3235	11
216	Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease.. 2022 , 11,	1
215	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week.. 2022 , 79, 1949-1962	1
214	. 2022 , 194, E620-E631	
213	Monitoring and Reversal of Anticoagulation and Antiplatelet Agents. 2022 , 491-502	
212	Primary and Rescue PCI in STEMI. 2022 , 154-166	

- 211 Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens. **2022**, 465-474
- 210 Oral Antiplatelet Agents in Percutaneous Coronary Intervention. **2022**, 420-438
- 209 PCI Strategies in Acute Coronary Syndromes without ST Segment Elevation (NSTEMI-ACS). **2022**, 146-153
- 208 Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. **2022**, 407-419
- 207 Drug-eluting stents and contemporary dual antiplatelet therapy in revascularized STEMI. The times they are a-changin'?. **2022**,
- 206 Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y Inhibitors.. **2022**, 27, 10742484221096524 2
- 205 Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. **2013**, 332-397 1
- 204 Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.. **2022**,
- 203 De-Escalation of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: An Updated Meta-Analysis and Trial Sequential Analysis of 21 studies and 38741 patients.. **2022**,
- 202 Precision Medicine Approaches for Management of Type 2 Diabetes. **2022**, 1-52
- 201 Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. **2022**, 20,
- 200 Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III). **2022**, 0
- 199 Shortening the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Systematic Review and Meta-analysis. **2022**, 0
- 198 One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs. **2022**,
- 197 Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme.
- 196 Age Considerations in the Invasive Management of Acute Coronary Syndromes. 16,
- 195 Rationale and Design of Switch Swedeheart: A Registry-Based, Stepped-Wedge, Cluster-Randomized, Open-Label Multicenter Trial to Compare Prasugrel and Ticagrelor for Treatment of Patients with Acute Coronary Syndrome. **2022**, 251, 70-70 1
- 194 Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. **2022**, 11, 3008 0

- 193 Newer P2Y12 Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis. **2022**, 97, 1074-1085 1
- 192 Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. **2022**, 97, 1041-1043
- 191 Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
- 190 Other Antithrombotics: Antiplatelets and Fibrinolytics. **2022**, 347-361
- 189 Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. **2022**, 23, 6982 1
- 188 Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury. **2022**,
- 187 Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance.
- 186 Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. 0
- 185 Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis. 9, 0
- 184 Recurrent Coronary Artery Thrombosis on Triple Anti-Thrombotic Therapy, Is There a Possible Association with ChAdOx1 nCoV-19 Vaccination?. **2022**, 11, 234-243
- 183 Experience with the use of combination antithrombotic therapy in a patient with acute coronary syndrome and underlying severe coronavirus infection. **2022**, 12, 60-68
- 182 Anti-platelet therapy post-AMI PCI: A collision between guidelines and the real world?. **2022**,
- 181 Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel. **2022**, 12, 30-45
- 180 Diagnosis and Management of Heart Disease. **2022**, 139-172
- 179 Best Practices in Pharmacotherapy for Acute Coronary Syndromes. 16,
- 178 EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. **2022**, 6, e750 0
- 177 Early Outcomes of Percutaneous Coronary Intervention in Patients with Cancer: A Systematic Review and Meta-analysis. **2022**, 101305
- 176 Resumption of Antiplatelet Therapy after Major Bleeding.

- 175 Synthesis of novel purine derivatives: antiplatelet aggregation activity evaluation and 3D-QSAR analysis. 0
- 174 The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
- 173 Balancing the Risks of Recurrent Ischaemic and Bleeding Events in a Stable Post ACS Population. **2022,**
- 172 Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?. 2
- 171 P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis. **2022,** 101, e29824
- 170 Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
- 169 Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. **2022,** 11, 3894
- 168 Nonsteroidal Antiinflammatory Drugs, Antiplatelet Medications, and Spinal Axis Anesthesia. **2023,** 316-327
- 167 Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. **2022,** 19, 8977 1
- 166 Temporal Trends in the Prevalence, Treatment and Outcomes of Patients with Acute Coronary Syndrome at High Bleeding Risk. **2022,** 12, 1784
- 165 Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
- 164 Invasively managed acute coronary syndrome in octogenarian patients: a retrospective cohort study. **2022,**
- 163 Aktuelle Aspekte und Strategien zum Einsatz oraler Antikoagulantien und Pflfchenfunktionshemmer in der Praxis.
- 162 Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china. 9,
- 161 Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy. **2022,** 146, 107089
- 160 The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent. **2022,** 11, 4465
- 159 Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review.
- 158 Herz und Diabetes.

157	Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial. 2022,	1
156	Safety and Efficacy of Low-dose Prasugrel in the Endovascular Treatment of Unruptured Aneurysms in the Elders (≥75 Years).	
155	Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention. 2022, 17, e0272140	
154	Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. 2022, 15,	1
153	Pharmacogenetics of Antiplatelet Therapy. 2023, 63,	0
152	Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.	
151	2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.	15
150	A Comprehensive Review of the Pleiotropic Effects of Ticagrelor.	1
149	Dual Antiplatelet Therapy: Guidance for Nurse Practitioners. 2022,	
148	Prescribing Trends and Health Care Expenditure of P2Y12 Prescriptions in Australia Over the Last Decade. 2022,	
147	Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a "target trial" 2022, 9, e001999	
146	Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis. 2022, 15,	3
145	The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack. 1-15	0
144	Trends in treatment and outcomes of patients with diabetes and acute myocardial infarction: Insights from the nationwide AMIS plus registry. 2022,	
143	Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy. 9,	0
142	Incidence and predictors of intracranial bleeding after coronary artery bypass graft surgery. 9,	
141	De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?. 9,	1
140	How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?. 2022, 365, 61-68	

- 139 Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability. **2022**, 75, 128969 ○
- 138 Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting. **2022**, 219, 70-76 ○
- 137 Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. **2022**, 133-198 ○
- 136 Prasugrel for Secondary Prevention of Thrombotic Stroke. **2022**, ○
- 135 Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects. **2022**, 11, 4888 ○
- 134 Impact of P2Y12 inhibitors on cardiovascular outcomes of Korean acute myocardial infarction patients with baseline thrombocytopenia. 9, ○
- 133 Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions. ○
- 132 Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. **2022**, 80, 1220-1237 ○
- 131 A Peculiar Case of Recurrent Coronary Artery Thrombosis. **2022**, ○
- 130 Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review. **2022**, 2022, 1-8 ○
- 129 Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry. **2022**, 33, 1270-1278 ○
- 128 The developmental journey of therapies targeting purine receptors: from basic science to clinical trials. ○
- 127 Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. **2022**, 11, 5605 ○
- 126 Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials. 13, 1
- 125 Perioperative medication management for older people. ○
- 124 P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention. **2022**, 9, 340 ○
- 123 Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?. 9, 1
- 122 EFFECTIVENESS AND SAFETY COMPARISON OF P2Y12 RECEPTOR INHIBITORS IN PATIENTS WITH INVASIVE STRATEGY FOR ACUTE CORONARY SYNDROME. **2022**, 23, 108-116 ○

121	Evaluation of Potential Racial Disparities in CYP2C19 -Guided P2Y 12 Inhibitor Prescribing after Percutaneous Coronary Intervention.	1
120	Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – a modified Delphi consensus by the ADVANCE Working Group.	0
119	Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk. 2022 , 20, 839-849	0
118	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk. 2022 , 15,	0
117	The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.	0
116	A pressing need and opportunity to standardize care in neurointerventional surgery. 2022 , 14, 1049-1050	0
115	Association of haemoglobin glycation index with outcomes in patients with acute coronary syndrome: results from an observational cohort study in China. 2022 , 14,	0
114	Sex-Related Differences in Thrombus Burden in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. 2022 , 15, 2066-2076	0
113	Contemporary Approaches to Reducing Morbidity and Mortality in Patients With Acute Coronary Syndromes. 2022 , 80, 1799-1801	0
112	Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.	1
111	PODOBIĘSTWA I RYZYK W TERAPIACH PRZECIWPŁYTKOWYCH W OSTRYCH ZESPÓŁACH WIEŃCOWYCH I UDARZE NIEDOKRWIENNYM MÓZGU. 2016 , 14, 25-33	0
110	Association between high-sensitivity C-reactive protein and bleeding in non-ST-segment elevation acute coronary syndrome: A multicentre cohort of Chinese population.	0
109	Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis. 2022 , 15, 906-914	0
108	Mortality of Escalation and Modulation Antithrombotic Therapy in Coronary Artery Disease Patients: A Meta-analysis of Randomized Controlled Trials.	0
107	Tratamientos antiplaquetarios. 2022 ,	0
106	Third Generation P2Y12 Inhibition for East Asian ACS Patients. 2022 , 2, 675-676	0
105	Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment. 2022 , 9, 397	0
104	Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how. 9,	0

- 103 Narrowing disparities in PCI outcomes in women; From risk assessment, to referral pathways and outcomes. **2022**, 24, 100225 ○
- 102 Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. **2022**, 39, 364-372 ○
- 101 Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study. ○
- 100 CABG Vs. PCI for Left Main Revascularization. **2022**, 21-34 ○
- 99 Statistical power considerations in the use of win ratio in cardiovascular outcome trials. **2023**, 124, 107040 ○
- 98 The Role of P2Y12 Inhibitor Monotherapy in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. 2, ○
- 97 Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping. **2022**, 27, 107424842211432 ○
- 96 Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention. **2022**, 15, 2270-2280 ○
- 95 Revisiting secondary prevention in coronary heart disease. **2022**, 74, 431-440 ○
- 94 Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors. **2022**, 11, 6856 ○
- 93 What is known in pre-, peri-, and post-procedural anticoagulation in micro-axial flow pump protected percutaneous coronary intervention?. **2022**, 24, J17-J24 ○
- 92 Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome after Percutaneous Coronary Intervention. ○
- 91 The Effect of a Prasugrel- versus a Ticagrelor-based Strategy on Total Ischemic and Bleeding Events in Patients with Acute Coronary Syndromes. ○
- 90 Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. ○
- 89 Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation. 9, ○
- 88 Efficacy and safety of clopidogrel versus ticagrelor for stabilized patients with acute coronary syndromes after percutaneous coronary intervention: results from a real-world registry in China. **2022**, Publish Ahead of Print, ○
- 87 Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs. **2022**, 15, 1532 ○
- 86 Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. **2023**, 34, ○

- 85 Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases. 089719002211450
- 84 Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study. ○
- 83 Association between P2Y12 inhibitor reloading and In-hospital Outcomes for patients with Non-ST-segment Elevation Acute Coronary Syndrome already on Chronic P2Y12 receptor inhibitors therapy in China: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project. ○
- 82 Antiplatelet Therapy in Coronary Artery Disease: Now and Then. ○
- 81 Sex differences in clinical profile and outcome after percutaneous coronary intervention for chronic total occlusion. **2022**, ○
- 80 Acute, periprocedural and longterm antithrombotic therapy in older adults. ○
- 79 Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?. **2022**, 11, 7211 ○
- 78 De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?. **2022**, ○
- 77 Strategies for Managing Solid Form Transformation Risk in Drug Product. **2022**, ○
- 76 Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial. ○
- 75 Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. 1-12 ○
- 74 Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial. **2022**, 11, ○
- 73 Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. **2022**, 11, 7440 ○
- 72 Akutes Koronarsyndrom. **2022**, 1-53 ○
- 71 Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor. ○
- 70 National Institute for Health and Care Excellence guidelines on myocardial revascularisation. heartjnl-2022-321397
- 69 Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome. **2023**, ○
- 68 Antithrombotic therapy in patients with diabetes mellitus. **2023**, 24, 737-750 ○

- 67 Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. **2023**, 1-65 0
- 66 Acute Coronary Syndrome in the Older Adult Populations. **2023**, 303-341 0
- 65 Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry. **2023**, 23, 0
- 64 Effectiveness and safety of P2Y12 inhibitor pretreatment for primary PCI in STEMI: Systematic review and meta-analysis. 0
- 63 Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI. **2023**, 16, 1-18 2
- 62 Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs. 0
- 61 An Old Problem in Need of New Solutions. **2023**, 0
- 60 Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function. **2023**, 0
- 59 Pharmacogenetics of P2Y 12 receptor inhibitors. 0
- 58 Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. **2023**, 24, 77-86 1
- 57 Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis. **2022**, Publish Ahead of Print, 0
- 56 The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. **2023**, 59, 84 1
- 55 Role of platelet function testing in acute coronary syndromes: a meta-analysis. **2022**, 9, e002129 0
- 54 Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. 9, 0
- 53 The framing of time-dependent machine learning models improves risk estimation among young individuals with acute coronary syndromes. **2023**, 13, 0
- 52 The Optimal Duration and De-escalation Strategy of Antiplatelet Agents and Anticoagulation Agents in Korean Patients Undergoing Percutaneous Coronary Intervention. 3, 0
- 51 ST-segment elevation myocardial infarction. **2023**, 13-33 0
- 50 Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries. **2023**, 48, 101608 0

49	Pharmacology and Clinical Development of Factor XI Inhibitors. 2023 , 147, 897-913	1
48	Fifteen-Year Nationwide Trend in Antiplatelet Treatment among Drug-Eluting Stent Recipients in Korea: Many Patients Receive Very Prolonged Dual-Antiplatelet Treatment, and Newer Drugs Are Replacing the Older Ones. 2023 , 12, 2675	0
47	Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI.	0
46	Gestione delle sindromi coronariche acute nelle prime 48 ore. 2023 , 28, 1-14	0
45	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2023 , 24, 453-471	0
44	Is Stent Thrombosis a Genetic Disease?. 2023 , 2, 100194	0
43	Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCCACS (improving care for cardiovascular disease in China-acute coronary syndrome) project. 2023 , 28,	0
42	Antithrombotische Therapie. 2022 , 233-263	0
41	Monitoring antiplatelet therapy: where are we now?. 2023 , 24, e24-e35	0
40	P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis. 2023 , 16, 232	0
39	Clopidogrel Use in <i>CYP2C19</i> Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention. 2023 ,	0
38	Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome. 2023 , 224, 46-51	0
37	Assessment of In-Hospital Mortality and Its Risk Factors in Patients with Myocardial Infarction Considering the Logistical Aspects of the Treatment ProcessâA Single-Center, Retrospective, Observational Study. 2023 , 20, 3603	0
36	Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome. 2023 , 12, 1627	0
35	Gastrointestinal bleeding in patients under anticoagulant and antiplatelet therapy - the optimal approach. 2022 , 3, 37-48	0
34	Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention. 2023 , 18, e0278993	0
33	miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. 2023 , 28,	0
32	Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. 2023 , 14, 578	0

- 31 Pharmacoeconomic analysis of personalized antiplatelet therapy in patients with acute coronary syndromer. **2023**, 53-62 ○
- 30 Past, Present, and Future of Management of Acute Myocardial Infarction. **2023**, 2, 51 ○
- 29 Hypoglycemia as a potential risk for patients taking clopidogrel: A systematic review and meta-analysis. 14, ○
- 28 Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. **2023**, 100607 ○
- 27 Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field. **2023**, 12, 2082 ○
- 26 Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. ○
- 25 Acute Coronary Syndromes. **2023**, 230-255 ○
- 24 Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study. **2023**, 9, 39-48 ○
- 23 Gender disparities in prevalence by diagnostic criteria, treatment and mortality of newly diagnosed acute myocardial infarction in Korean adults. **2023**, 13, ○
- 22 Thrombozytenaggregationshemmung nach Koronarintervention (PCI). **2023**, 19, 41-56 ○
- 21 Pretreatment with P2Y12 Receptor Inhibitors in Acute Coronary Syndromes—the Current Standpoint of ESC Experts Sufficiently Supported?. **2023**, 12, 2374 ○
- 20 Guided vs. conventional anti-platelet therapy for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials. 10, ○
- 19 Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction. Volume 16, 1255-1266 ○
- 18 Nonsteroidal Antiinflammatory Drugs, Antiplatelet Medications, and Spinal Axis Anesthesia. **2013**, 375-384 ○
- 17 Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—a Translational Perspective. **2023**, 24, 6280 ○
- 16 Acute coronary syndrome in very elderly patients—real-world experience. ○
- 15 Clinical outcomes in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary interventions later than 48 h after symptom onset. ○
- 14 Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?. 1-5 ○

- 13 Current concepts and novel targets for antiplatelet therapy. ○
- 12 Antithrombotic regimens for the prevention of major adverse cardiac events in chronic coronary syndrome: A systematic review and network meta-analysis. 10, ○
- 11 Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. ○
- 10 Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions. 2023, 10, 163 ○
- 9 Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India. ○
- 8 Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. ○
- 7 Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. 2023, 6, e238585 ○
- 6 Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. ○
- 5 Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. 1-18 ○
- 4 Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach. 15, 142-153 ○
- 3 Tratamiento de los síndromes coronarios agudos en las primeras 48 horas. 2023, 49, 1-15 ○
- 2 A meta-analysis of cyp2c19 gene testing on the prognosis of patients aged 60 years and older with acute coronary syndrome. 2023, 2, 20-23 ○
- 1 The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome. 2023, 2023, 1-9 ○